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ABSTRACT 
 
Thiaminase I from Clostridium botulinum cleaves thiamin to the constituent 
pyrimidine and thiazole using a wide range of external nucleophiles. The crystal structure 
of the thiamin bound mutant of thiaminase I from Clostridium botulinum revealed the 
complete active site architecture and all the catalytically important residues were 
identified. The role of each active site residue was determined by its position and the 
steady-state kinetic study of the mutant of the corresponding residue. Based on the 
structural and the kinetic data, the mechanism of thiaminase I is proposed. Thiaminase I 
accepts a wide variety of cysteine containing nucleophiles, suggesting the possibility of 
some protein or peptide as its natural nucleophile. A plate assay and an HPLC based assay 
were developed to identify new thiaminase producing bacteria.  
The second part of the thesis is focused on the development of synthetic strategies 
for thiamin analogs to answer the following biological questions. Firstly, methoxythiamin 
pyrophosphate synthesized to study the effect of bacimethrin on thiamin-dependent 
enzymes and 13C and 15N labeled thiamin analog was synthesized to study different 
intermediate states of thiamin in PDC. Inhibition of thiamin-dependent enzymes was 
observed and the data indicates that the toxicity arises due to a different binding mode of 
2’-methoxythiamin in the active site. Secondly, two fluorine labeled thiamin analogs were 
designed that can be used as a tracer for PET imaging study in live animals. Thirdly, 
synthetic methodologies have been developed to utilize thiamin molecule as a delivery 
vehicle. The impermeable cargo molecules attached to thiamin molecule via ester or 
 iii 
 
carbamate linkage can be delivered inside the cells through membrane transporters of 
thiamin. Finally, synthesis of thiochrome was utilized to estimate thiamin content in 
auxotrophic phytoplankton and preferential utilization of pyrimidine precursors were 
observed to fulfill the thiamin requirement. 
Preliminary studies were done to explore a putative methanopterin 
methyltransferase MJ0619. This enzyme is air sensitive and copurifies with bound 4Fe-
4S clusters. MJ0619 contains at least three 4Fe-4S clusters and can cleave SAM 
homolytically in reducing conditions, which classifies it as a radical SAM enzyme. It also 
possesses GTP cyclohydrolase activity to produce 7,8-dihydroneopterin cyclic phosphate 
from GTP and can cleave N-glycosidic bond of several nucleosides. Methylation of 7,8-
dihydro-6-hydroxymethyl pterin is also observed with this enzyme, however the sources 
of the methyl groups are still unknown. 
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CHAPTER I  
INTRODUCTION TO THIAMINASE I AND ITS MECHANISTIC INVESTIGATION 
BY STRUCTURAL AND KINETIC STUDIES 
 
1.1 Introduction to thiamin 
Thiamin (1), commonly known as vitamin B1, is an important cofactor in all forms 
of life. Bacteria, fungi and plants can biosynthesize thiamin de novo, however, the 
biosynthetic genes of thiamin are absent in animals, and they have to acquire it from their 
diet. The thiamin molecule is comprised of a pyrimidine ring and a thiazole ring linked by 
a bridging methylene group. Thiamin is biosynthesized as thiamin monophosphate (2), 
however, it can be found as diphosphate (3) and free thiamin as well (Figure 1.1). The 
other two forms of thiamin include thiamin triphosphate and adenylated thiamin.1 
 
 
 
 
Figure 1.1: Structure of thiamin and its phosphates.  
 
1.1.1 Degradation of thiamin and reaction catalyzed by thiaminase 
Thiamin is a stable cofactor in neutral and acidic conditions. In basic medium the 
thiazole ring of thiamin hydrolyzes to form ring open thiamin (4) which might get oxidized 
to form a dimer known as thiamin disulfide (5) (Figure 1.2). Temperature, oxidizing and 
reducing agents also cause damage to the thiamin molecule.2 Apart from the chemical and 
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environmental degradation, thiamin can also be degraded by action of enzymes called 
thiaminases that are subdivided into two categories. Thiaminase I uses a wide range of 
nucleophiles for the cleavage reaction whereas thiaminase II uses only water for this 
purpose (Scheme 1.1).3-5  
 
 
 
 
Figure 1.2: Structure of ring open thiamin and thiamin disulfide. 
 
 
 
 
Scheme 1.1: Reaction catalyzed by thiaminase. For thiaminase II, X = Water and for 
thiaminase I, X can be a variety of nucleophiles. Thiaminase II only uses water as a 
nucleophile, however, thiaminase I can use a variety of nucleophiles to cleave thiamin.  
 
 
Thiaminase II is distinct from thiaminase I both in terms of structure and 
sequence.6 Intake of thiaminase containing food or infection by thiaminase producing 
organisms in the body or food material cause lower levels of thiamin and symptoms of 
thiamin deficiency.7-10 Effect of thiamin deficiency in humans can result in wet beriberi 
(affecting cardiovascular system) or dry beriberi (affecting nervous system) with fatal 
consequenses.11-12 
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1.1.2 Thiaminase I and its proposed mechanism 
Thiaminase I was first identified about a decade ago, however, its mechanism was 
unclear at that time.13-14 Thiaminase I from Bacillus thiaminolyticus (Bt-thiaminase) was 
first discovered as an extracellular protein and was further characterized by recombinant 
expression in E. coli.15-16 Leinhard and co-workers first proposed the formation of an 
enzyme-pyrimidine adduct intermediate during the reaction via kinetic evidence and 
thereby proposed a mechanism of the reaction.4 This idea was further supported by 
inhibition of thiaminase I from B. thiaminolyticus by 4-amino-5-(aminomethyl)-6-chloro-
2-methyl pyrimidine (6).17 The only cysteine of the enzyme was identified as the active 
site nucleophile forming the covalent linkage with the substrate and later the inactive 
enzyme was crystallized and a mechanism is proposed (Figure 1.3).3, 18 It has also been 
observed that in the reaction of pyrimidine adduct formation the configuration of the 
methylene carbon is retained suggesting that the nucleophile attacks from the same 
direction that the thiazole moiety leaves.19 In alkaline pH thiaminase I also degrades 
thiamin very slowly for few turnovers and releases the thiazole moiety, however, no HMP-
OH (7, X = OH) was formed, the fate of the pyrimidine part was later discovered as the 
adduct of the ring open thiamin.20  
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Figure 1.3: Proposed mechanism for Bt-Thiaminase I. Structure did not identify all the 
catalytic residues. 
 
1.1.3 Structural aspects of thiaminase I 
Thiaminase I from Bacillus thiaminolyticus is structurally homologous to the 
group II periplasmic binding proteins (PBPs).6, 21 PBPs are responsible for binding small 
molecules and delivering them to the ABC-type transporter for cellular uptake. These 
proteins have two conformations, open conformation with no ligand bound and a closed 
conformation with the ligand bound.21 Bt-thiaminase is structurally similar to the 
periplasmic thiamin-binding protein (TbpA) which is the carrier of thiamin, thiamin 
monophosphate and thiamin diphosphate for many prokaryotes.22 The eukaryotic thiamin 
pyrimidine synthase, Thi5, is a member of the group II PBP superfamily and also a 
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structural homolog to ThiY.23-24  ThiY is a periplasmic protein that is used by some 
prokaryotes for binding N-formyl HMP, which is a thiamin degradation product.25  
The reported structure of Bt-thiaminase, crystallized with mechanism-based 
irreversible inhibitor 4-amino-6-chloro-2,5-dimethylpyrimidine (Figure 1.4), showed that 
the active site is located in a V-shaped cleft between its two domains.18 An interesting 
similarity is observed between its active site location and the ligand binding sites of PBPs. 
The activator glutamate residue, responsible for the deprotonation of the catalytic cysteine 
for the nucleophilic attack at C6, is also observed in the structure. Despite the major 
differences in their size, structure, and sequence, thiaminase-I and most of the thiaminase-
II use a cysteine residue for the covalent linkage formation. 
 
Figure 1.4: Crystal structure of Bt-Thiaminase I active site. 
 
A new thiaminase-I is discovered in Clostridium botulinum associated with the 
biosynthetic gene cluster of Bacimethrin, a thiamin antivitamin.26 It has 51% sequence 
identity with Bt-thiaminase. The catalytic cysteine residue was identified by sequence 
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alignment with other thiaminase-I(s) and it was mutated to design an inactive enzyme. The 
mutant enzyme was co-crystallized with the substrate thiamin and the first structure of 
thiaminase I complexed with substrate was reported by our collaborator Ealick research 
group from Cornell University.27 This structure reveals the complete active site structure 
and the residues involved in binding and catalysis are identified. Kinetic studies on 
appropriately chosen mutants of these residues can confirm their roles in the catalysis 
assigned by the structural data providing a better understanding of the enzyme’s 
mechanism. A search for the natural nucleophile of Cb-thiaminase I was also conducted. 
Primarily cysteine containing nucleophiles are screened against Cb-thiaminase to test 
whether some protein can act as the natural nucleophile for the thiaminase catalyzed 
reaction. 
Thiaminase enzymes are responsible for numerous well-documented thiamin 
deficiency case studies involving humans, fish, horses, cattle, sheep, chickens, and foxes 
and appear to be globally distributed.  However, the extent of thiaminase distribution on 
land and water and their physiological significance is still unclear.  Considering the impact 
of thiamin deficiency caused by thiaminases upon the animal kingdom, the distributions 
and roles of these enzymes in the environment need greater clarification.  To that end, 
unidentified soil bacteria from China, which showed thiamin catabolic properties were 
screened for thiaminase I activity.  The subsequent discovery of new thiaminase I-
producing bacteria is discussed herein. 
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1.2 Results 
1.2.1 Active site architecture of the Cb-Thiaminase 
 
 
 
 
 
 
 
Figure 1.5: X-ray crystal structure of the C143S mutant of the Cb-Thiaminase active site 
with thiamin bound. All six catalytically active residues are shown. The structure gives a 
good indication of the positions of the residues around the substrate and their possible 
roles in the catalysis. 
 
Our collaborator Ealick research group at Cornell University has determined the 
crystal structure of the Cb-thiaminase C143S with bound thiamin in the active site at 2.2 
Å resolution. The structure of the protein appeared to be a dimer containing residues 39-
404 for the first monomer and 40-404 for the second one. Size exclusion chromatography 
showed that Cb-thiaminase is a monomer in solution. This structure also clearly reveals 
the substrate-binding site (Figure 1.5). Each monomer has a thiamin molecule bound in 
its V-shaped cleft (dimensions: depth – 17 Å, length – 15 Å and width - 12 Å.). There are 
six tyrosine residues at the outer collar of the cleft, and most of the active site residues are 
located at the bottom of it. Thiamin binds to the active site in the F-conformation with 
E271 
C143 
D302 
D94 
Y80 
Y46 
Thiamin 
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torsion angles of ϕT = −10° (C5′−C7′−N3−C2) and ϕP = −93.6° (N3−C7′−C5′−C4′) and 
the N3−C7′−C5′angle is 108°.28 The dihedral angle between the planes of pyrimidine and 
the thiazolium ring is 85.9o suggesting that they are almost perpendicular to each other. 
The pyrimidine part is positioned towards the bottom of the binding pocket, and the 
thiazole part is pointed outward. The pyrimidine is in the hydrogen bonding distance with 
Asp302, Asp94 and Glu271 (Figure 1.6). However, the thiazolium group does not interact 
with the enzyme except through van der Waals contacts with the 5-hydroxyethyl group 
extended out toward the solvent region. 
 
 
 
Figure 1.6: 2-dimensional representation of the Cb-Thiaminase active site. All distances 
are given in Å. 
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1.2.2 Reconstitution of wild-type Cb-thiaminase 
 
Scheme 1.2: Reaction used for the kinetic study of Cb-Thiaminase I 
 
  
Mercaptoethanol was used as the nucleopile to study the kinetic proterties of Cb-
Thiaminase I. Several reaction conditions were tried to optimize the activity for thiamin 
cleavage reaction (Scheme 1.2). The enzyme was found to be active at room temperature. 
The reaction was carried out in buffers of different pH and the highest kcat was observed 
at pH 8.0 (Figure 1.7). 
 
 
 
 
 
 
 
Figure 1.7: Plot of observed kcat vs. pH of the reaction buffer. pH 8.0 shows a maximum 
value of kcat reflecting highest activity. 
 
The reaction mixture was analyzed by HPLC to observe the formation of the 
products. No product formation was observed in no enzyme or no thiamin control (Figure 
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1.8). Some product formation was observed in no thiol control due to the presence of ring-
open thiamin in the reaction mixture.20  
 
 
 
 
 
 
 
 
Figure 1.8: HPLC chromatogram of the Cb-Thiaminase reaction mixture with all controls. 
 
1.2.3 Choice of active site mutants for kinetic characterization 
All the active site residues were identified from the crystal structure. Six residues 
were found that are directly interacting with the substrate molecule or the residues 
involved in the catalysis. Six mutants were prepared, and one of these six amino acids 
were mutated in each of them. All these mutants were overexpressed, and the kinetic 
parameters were determined. Role of each mutated amino acid was rationalized from the 
data. 
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List of mutants 
 CbThi1(pTHT) Y80F    -------   (A) 
 CbThi1(pTHT) C143S   ------    (B) 
 CbThi1(pTHT) D302N  ------    (C) 
 CbThi1(pTHT) E271Q   ------   (D) 
 CbThi1(pTHT) Y46F     -------  (E) 
 CbThi1(pTHT) D99N     ------   (F) 
 
1.2.4 Steady-state kinetics of the wild-type enzyme 
 
Figure 1.9: Steady-state kinetics of the cleavage of thiamin catalyzed by wild type 
enzyme. Assays were carried out in 0.1 M potassium phosphate buffer, pH 8.0, 0.1 M KCl, 
in the presence of 713 mM 2-mercapto ethanol and 0.1 M enzyme. The kcat value was 
recorded as 230 ± 11 s-1 and the KM for thiamin was 452 ± 50 uM 
 
The kcat and the KM of the wild-type enzyme were measured and used as the 
standard with which kinetic constants of all other mutants were compared. The wild-type 
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enzyme was the fastest among all the mutants with the highest kcat value of ~ 230 s
-1. The 
role of each active site residue in the catalysis was deduced by comparing the kcat of the 
corresponding mutant with the wild type.  
 
1.2.5 C143S mutant of Cb-Thiaminase I 
 
 
 
 
 
 
Figure 1.10: Position of the Cysteine-143 in the active site. C143 is mutated to serine to 
get a substrate bound crystal structure in C143S mutant 
 
C143 is the key catalytic residue in Cb-Thiaminase I (Figure 1.10). It adds to the 
C6 of the pyrimidine ring by a nucleophilic addition reaction and forms a covalent adduct. 
This activates the thiamin molecule and displaces the thiazole moiety. Addition of an 
external nucleophile takes place after that. When C143 is mutated to serine, the enzyme 
appears to be non-functional and no product formation was detected by HPLC after 4 
hours of incubation. As serine is not as nucleophilic as cysteine, the activation of the 
pyrimidine ring of thiamin molecule cannot happen. However, serine is the closest amino 
acid to cysteine regarding size and shape, so it does least perturbation to the active site 
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geometry. Thus the thiamin bound crystal structure of this mutant protein gives the most 
accurate and reliable structure of the active site. 
 
1.2.6 Y80F mutant of Cb-Thiaminase I 
 
 
 
 
 
Figure 1.11: Position of Y80 in the active site. The stacking alignment right in parallel to 
the thiazole ring of the thiamin showing a possibility of potential electrostatic interaction 
of its hydroxyl group with the positively charged nitrogen. Hydrogen bonding interaction 
with D94 and Y46 is also evident. 
 
Tyr-80 is the unique residue in the active site whose phenyl ring stays in parallel 
to the thiazole ring of the thiamin molecule (Figure 1.11). Such critical positioning of this 
residue initially suggested a pi stacking type interaction between the two aromatic 
systems. Corresponding phenylalanine mutant should sustain this interaction and not 
much difference in the kinetic constants was expected. However, the increment of the KM 
to 2 ± 0.1 mM in this mutant ruled out that possibility, indicating a different type of 
interaction between the tyrosine and substrate thiazolium. A closer look on the structure 
revealed that the oxygen atom of the phenolic hydroxyl group of this tyrosine is directly 
over the thiazole ring nitrogen, and the distance is 3.6 Å (Figure 11). Both the structural 
and the kinetic data leads to the proposal that the oxygen atom of Y80 hydroxyl group 
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electrostatically interacts with the positively charged thiazolium ion. The resulting binding 
energy is used for substrate binding and catalysis. After the detachment of the thiazole 
ring from thiamin, the positive charge on it is lost, and Y80 also loses hydrogen bonding 
with D94 facilitating the departure of thiazole as a product. 
 
 
Figure 1.12: Steady-state kinetics of thiamin cleavage by 2-mercapto ethanol catalyzed 
by Y80F mutant. 0.1 M potassium phosphate buffer, pH 8.0, 0.1 M KCl, in the presence 
of 713 mM 2-mercapto ethanol and 3.1 M enzyme. The kcat value was recorded as 1.1 ± 
0.1 s-1 and the KM for thiamin was 2 ± 0.1 mM. 
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1.2.7 D302N mutant of Cb-Thiaminase I 
 
 
 
 
 
Figure 1.13: Position of D302 in the active site. Hydrogen bonding type interaction 
observed between the aspartate and the pyrimidine N-3 of thiamin. 
 
Asp-302 is situated in a hydrogen bonding distance from both the N-3 and the C-
4 amino group of the pyrimidine ring of bound thiamin (Figure 1.13). The hydrogen 
bonding capabilities of aspartate and asparagine for the pyrimidine ring nitrogen atoms 
are similar, which is reflected in the similarity in the KM value between wild-type enzyme 
and D302N mutant (Table 1.1). A small decrease in KM is observed as the substrate spends 
more time in the active site due to slow reaction rate (Figure 1.14). However, the kcat value 
is decreased by 28 fold which indicates its involvement in catalysis. It forms hydrogen 
bond type interaction with pyrimidine ring nitrogen making the ring more electron 
deficient, and thus activates the ring for the nucleophilic addition of C143 at C6. The 
activation process takes higher energy for the amide compared to the acid due to the 
difference in hydrogen bond energy, and that makes the rate slower. 
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Figure 1.14: Steady-state kinetics of thiamin cleavage by 2-mercapto ethanol catalyzed 
by D302N mutant. 0.1 M potassium phosphate buffer, pH 8.0, 0.1 M KCl, in the presence 
of 713 mM 2-mercapto ethanol and 0.3 M enzyme. The kcat value was recorded as 
8.10.7 s-1 and the KM for thiamin were 0.3  0.1 mM 
 
 1.2.8 E271Q mutant of Cb-Thiaminase I 
 
 
 
 
 
 
 
Figure 1.15: Position of E271 in the thiamin bound structure. The cysteine has been 
mutated to serine. It is in hydrogen bonding distance from both the substrate and the 
catalytic cysteine. 
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This mutant has a comparable KM value with the wild type enzyme however, a 
large decrease in the kcat value is observed. The structure shows that Glu-271 is within the 
hydrogen bonding distance from the N-1 of the substrate thiamin and the thiol group of 
the cysteine (Figure 1.15). However, this dipolar interaction would be present with 
glutamine as well. Glu-271 has a dual function in the catalysis. It serves as the base to 
C143 and generates the sulfide nucleophile and acts as an acid to protonate the N1 of the 
pyrimidine.  Decrease in kcat value in the order of four reflects the big difference in the 
proton abstraction capability between glutamate and glutamine from the thiol group and 
thus its importance in the catalysis. The decrease in KM value is consistent with KM 
approaching Kd when the chemical steps are retarded. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.16: Steady-state kinetics of thiamin cleavage by 2-mercapto ethanol catalyzed 
by E271Q mutant. 0.1 M potassium phosphate buffer, pH 8.0, 0.1 M KCl, in the presence 
of 713 mM 2-mercapto ethanol and 23.6 M enzyme. The kcat value was recorded as (11 
 0.3) x 10-3 s-1 and the KM for thiamin was 75  12 M. 
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1.2.9 Y46F mutant of Cb-Thiaminase I 
 
 
 
 
 
 
 
Figure 1.17: Position of Tyr 46 in the active site. The distance between Y46 and Y80 is 
suitable for hydrogen bonding. 
 
Minimal effect on kcat and KM was observed upon mutating Tyr-46 to 
phenylalanine. The structure shows that the Tyr-46 phenolic hydroxyl group is in 
hydrogen bonding distance with the Tyr-80 phenol (Figure 1.17). The residue is most 
likely to modulate the pKa of Y80. There is an only four-fold decrease in the kcat value 
indicating that Tyr80-Tyr46 hydrogen bond is not critical in the catalysis. A ten-fold 
increase in the KM value suggests its importance in controlling the electrostatic interaction 
between Tyr-80 and the substrate. It may have some effect on Asp-302 protonation state 
as the distance between them is only 4.0 A. 
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Figure 1.18: Steady-state kinetics of thiamin cleavage by 2-mercapto ethanol catalyzed 
by Y46F mutant in 0.1 M potassium phosphate buffer, pH 8.0, 0.1 M KCl, in the presence 
of 713 mM 2-mercapto ethanol and 0.07 M enzyme. The kcat value was recorded as 61  
4 s-1 and the KM for thiamin was 240  50 M. 
 
1.2.10 D94N mutant of Cb-Thiaminase I 
  
 
 
 
 
 
 
 
Figure 1.19: Position of the D94 residue in the structure. Possible hydrogen bonding 
distance with Y80 phenol and the pyrimidine C4’ amino group is shown.  
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D94 deprotonates the C4 amino group of the thiamin pyrimidine and activates it 
for the expulsion of thiazole (Figure 1.19). It also reprotonates the pyrimidine-imine in 
concert with the addition of the nucleophile to the methylene group. Since the proton 
abstraction step is obstructed in this mutant, a big change in kcat is highly expected. It is 
presumed to play some role in the initial steps of substrate binding by hydrogen bond 
formation with the hydroxyl group of Tyr80 thereby accumulating partial negative charge 
on the oxygen and this interaction is lost in the mutant. 
 
 
 
 
 
 
 
 
Figure 1.20: Steady-state kinetics of thiamin cleavage by 2-mercapto ethanol catalyzed 
by D94N mutant. 0.1 M potassium phosphate buffer, pH 8.0, 0.1 M KCl, in the presence 
of 713 mM 2-mercapto ethanol and 13 M enzyme. The kcat value was recorded as 0.23  
0.02 s-1 and the KM for thiamin was 3.5  0.8 mM. 
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Table 1.1: Kinetic properties of thiaminase activity for  Cb-Thiaminase I and six 
active site mutants 
 
 
Mutant Kcat (s
-1) KM (M) Kcat / kM (M
-1s-1) 
WT 230  11 (452 ± 50) x 10-6 (51 ± 6.2) x 104 
C143S - - - 
Y80F 1.1 ± 0.1 (2 ± 0.1) x 10 -3 550 ± 57 
D302N 8.1  0.7 (0.3  0.1) x 10-6 (27  9.3) x 103 
E271Q (11  0.3) x 10-3 (75 ± 12) x 10-6 150 ± 24 
Y46F 61  4 (240 ± 50) x 10-6 (25 ± 5.6) x 104 
D94N (23  2) x 10-2 (3.5  0.8) x 10-3 70 ± 16 
 
 
1.2.11 Search for the natural nucleophile of thiaminase I 
All the nucleophiles that thiaminase I was tested with, are primarily synthetically 
prepared organic compounds. However, in the natural habitat, it must use some 
nucleophile that is available in the environment. Pyridoxal was reported as a nucleophile 
for Bt-thiaminase I, which is a naturally occurring cofactor, however, keeping the 
efficiency of thiol-containing nucleophiles in mind cysteine and cysteine-containing 
peptides are the obvious guesses as a natural nucleophile. Cysteine, methyl ester of 
cysteine and N-acetyl cysteine were all accepted as a nucleophile by Cb-thiaminase I while 
the methyl ester of cysteine showed highest efficiency and N-acetyl cysteine showed the 
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lowest (Figure 1.21).  There was no selectivity between D and L-cysteine by Cb-
thiaminase I while choosing them as nucleophiles. 
 
 
 
 
 
 
Figure 1.21: HPLC Chromatogram of the reaction of thiamin with Cysteine and cysteine 
ester as a nucleophile for Cb-Thiaminase. 
 
After observing the acceptance cysteine and its derivatives as nucleophiles, we 
looked towards cysteine containing peptides. Small peptides with cysteine in the terminal 
position and non-terminal positions were tested. In both cases, consumption of the 
substrate and formation of new product confirms their acceptance as nucleophiles (Figure 
1.22). 
  
 
 
 
 
 
Figure 1.22: HPLC Chromatogram of the reaction of thiamin with Cysteine-containing 
peptides B) Gly-Cys-Gly-Gly as a nucleophile for Cb-Thiaminase I. 
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1.2.12 Development of a methodology to identify thiaminase secreting bacteria 
Our collaborator Dr. Xiaohong Jian provided soil bacteria from locations in the 
United States and China with apparent thiamin catabolic properties.  They were 
categorized “EK1 (1.1-1.8)”, “EK2 (2.1-2.2)”, and “EK3 (3.1-3.5)” depending on their 
source of origin.  The bacteria were further screened for thiamin degrading properties both 
individually and in groups using a previously reported diazonium reagent with overlaid 
soft agar technique.29  The plate assay gave clear and easily interpretable positive results, 
as reported with known thiaminase I producer Bacillus thiaminolyticus (Figure 1.23A) and 
Burkholderia thilandensis (Figure 1.23B) and an appropriately negative result for E. coli 
as a negative control. However, the results obtained for the experimental strains were at 
times unreproducible and difficult to interpret.  A new methodology based on HPLC 
analysis was therefore developed to identify thiaminase I activity more directly. 
 
 
 
 
 
 
 
Figure 1.23: A) Plate assay with Bacillus thiaminolyticus. B) Comparison of thiaminase-
producing B. thailandensis colonies vs. E. coli colonies in the plate assay. Degradation of 
thiamin (yellow halo around the colonies) is observed for thiaminase producing strains. 
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To carry out the HPLC assays, the sets of unknown bacteria were grown 
individually and in combinations, in minimal media in the presence of thiamin and 2-
mercaptoethanol. After the growth, filtered media was analyzed by HPLC to observe any 
thiaminase activity. As thiaminase enzyme is secreted outside, it will catalyze the reaction 
between thiamin and the thiol to produce thiazole as a product. E. coli culture was used as 
the control, and the blank media was also tested. The thiamin degradation was normalized 
by cell density in the culture. Figure 1.24 summarizes the results of the HPLC analysis. It 
has been observed that EK 1.4, EK-3.3 and EK-3.5 are the only three strains that showed 
moderate thiaminase activity when grown individually. The combination of several EK 
strains exhibited degradation of thiamin more efficiently, suggesting some intercellular 
signaling for thiamin secretion (Figure 1.24). Further investigations are underway to 
identify the thiaminase gene and downstream catabolic pathway. 
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Figure 1.24:  Normalized peak area of the produced thiazole in the HPLC assays 
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Figure 1.25: Proposed mechanism based on the structural and the kinetic data. 
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1.3 Discussion 
The reaction catalyzed by Cb-thiaminase I follows a ping-pong type mechanism. 
Firstly, a nucleophilic attack by the active site cysteine takes place on the substrate and 
the thiazole moiety leaves. It is followed by the addition of an external nucleophile on the 
pyrimidine moiety to form the pyrimidine-nucleophile adduct. Based on the positions of 
the active site residues and the kinetic data of the mutants, a detailed mechanism of the 
reaction is proposed (Figure 1.25). At the beginning of the catalytic cycle, D94 stays in an 
anionic form, which can form a hydrogen bond with the Tyr80 phenol. Y46 also forms a 
hydrogen bond with Tyr80 phenolic hydroxyl group. These two interactions make the 
Tyr80 hydroxyl oxygen partially negative and anchor it in a position where it can bind to 
the thiazolium of thiamin electrostatically and can hold it in a position perpendicular to 
the plane of the pyrimidine moiety perfect for its departure as a leaving group. Asp302 
binds at the N3 atom of thiamin pyrimidine in the active site by forming hydrogen bond 
and activates the ring for nucleophilic attack. Glu-271 deprotonates the cysteine creating 
a free sulfide nucleophile which then attacks the C-6 of the activated thiamin pyrimidine 
forming a covalent linkage. After D94 abstracts a proton from the amino group of thiamin 
the hydrogen bonding with Y80 is lost, and the electrostatic interaction between Y80 and 
thiazolium is disrupted. Loss of the stabilization factor facilitates the departure of thiazole 
as a leaving group. Finally, an external nucleophile attacks at the electrophilic methylene 
carbon and all the catalytic steps are reversed. After the release of pyrimidine product, the 
enzyme becomes ready for its next cycle (Figure 1.25).  
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Cb-thiaminase I accepts cysteine, its derivatives and oligopeptides with cysteine in both 
the terminal and non-terminal position as nucleophiles for thiamin cleavage. This 
observation indicates that some cysteine or thiol containing natural products like 
glutathione or a peptide with an exposed cysteine residue can act as the natural nucleophile 
for thiaminase I. Thiaminase producing bacteria secrete the enzyme, which can then cleave 
thiamin in the surrounding in the presence of an external nucleophile. Degradation of 
thiamin can be detected by analyzing the growth media with HPLC. Three new putative 
thiaminase-producing strains were detected using this newly developed HPLC assay. This 
observation will potentially contribute towards the identification of the thiaminase gene 
and discovery of the first thiamin catabolic pathway in bacteria. 
 
1.4 Experimental Methods and Materials 
1.4.1 Cloning, overexpression and purification of Cb-Thiaminase I  
Our collaborator Ealick research group cloned the thiaminase I gene bcmE from 
C. botulinum str. ATCC 19397.The gene was inserted into pTHT, a modified pET-28 
plasmid containing a tobacco etch virus (TEV) protease cleavage site after the N-terminal 
His6 tag. Standard PCR-based site-directed mutagenesis protocol was used to construct all 
the mutants.30 
The plasmid containing the bcmE or mutant gene was transformed into E. coli 
BL21(DE3) cells and were grown in kanamycin (40 g/mL) containing agar. Starter 
cultures (15 mL) were grown from single colony overnight at 37 oC. To grow larger 
cultures, 10 mL of the starter culture was added directly to 1.5 L of sterile LB media and 
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were shaken at 37 oC until OD600
 reaches 0.6. The incubator temperature was reduced to 
15 oC and isopropyl -D-1-thiogalactopyranoside (IPTG) was added to a final 
concentration of 0.5 mM to initiate protein overexpression. After 18 hours of shaking at 
15 oC, the cells were harvested by centrifugation at 5000 rpm for 15 minutes. The cell 
pellet was collected after discarding the spent media and stored at -80 oC.  
The cell pellet was later thawed and resuspended in 45 mL of lysis buffer (100 mM 
KPi, 150 mM NaCl, ten mM imidazole, pH 7.8) containing 20 mg lysozyme, and lysed by 
sonication. The lysed cells were then centrifuged at 15000 rpm for 30 min at 4 oC. After 
discarding the cell debris, the supernatant was loaded onto a five mL Ni-Nitrilo acetic acid 
column, freshly charged and preincubated with lysis buffer. The column was washed with 
45 mL of the lysis buffer, 4 column volume of the wash buffer (100 mM KPi, 150 mM 
NaCl, 50 mM imidazole, pH 7.8) and then the protein was eluted with 2 column volumes 
of the elution buffer (100 mM KPi, 150 mM NaCl, 2000 mM imidazole, pH 7.8). The 
purity of the protein fractions was checked by SDS-PAGE gel. The pure fractions were 
pooled and concentrated and buffer exchanged with the storage buffer (100 mM KPi, 150 
mM NaCl, 15% glycerol, pH 7.5). The purified protein was stored in 100 L aliquots at -
80 oC freezer. 
 
1.4.2 Determination of the kinetic parameters 
Steady state kinetic analysis was performed for six Cb-thiaminase I mutant 
proteins that were selected on the basis of the crystal structure of the C143S/thiamin 
complex. Reactions were carried out in 100 mM potassium chloride and 50 mM phosphate 
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buffer at pH 8.0 using 713 mM β-mercaptoethanol as the exogenous nucleophile. For the 
pH profile of the enzymatic reaction, sodium acetate – acetic acid buffer system was used 
for the pH range 4.0 – 5.5.  All reactions were incubated at 25 °C except the E271Q Cb-
thiaminase I, which was measured at 37 °C due to low activity levels. The reactions were 
initialized by the addition of enzyme to the reaction volume containing thiamin, with 
thiamin concentrations ranging from 100 μM to 20 mM. Aliquots were taken from the 
reaction mixture after defined time intervals, quenched with 1 M HCl, neutralized, filtered 
through a 10 000 Da cutoff membrane to remove the enzyme and analyzed by HPLC. In 
the HPLC method, the ratio of 100 mM phosphate buffer at pH 6.6 (P) to methanol 
(M)/water mixture was varied over time in minutes (t). The gradient was carried out 
following the scheme (t, M%, H2O%, P%): (0, 0, 0, 100), (5, 0, 10, 90), (9, 15, 25, 60), 
(14, 65, 20, 15), (19, 0, 0, 100), (25, 0, 0, 100). Peak areas of the product in the enzyme e 
assays were measured and the concentrations were calculated based on a calibration curve 
relating peak area to 4-methyl-5-hydroxyethylthiazole concentration. The initial rates 
were calculated from plots of product concentration against time. Initial rates were then 
plotted and fit to the Michaelis−Menten equation for calculation of kinetic parameters. 
 
1.4.3 Assay condition to explore cysteine containing nucleophiles 
Reactions were carried out in 100 mM potassium chloride and 50 mM phosphate 
buffer at pH 8.0 using various cystenyl nucleophiles with the final concentration of 10 
mM The reactions were initialized by the addition of enzyme to the reaction mixture  
containing 1 mM thiamin. All reactions were incubated at 37 °C for 2 hours and then the 
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reaction was quenched with 1 M HCl, neutralized, filtered through a 10 000 Da cutoff 
membrane to remove the enzyme and analyzed by HPLC.  
 
1.4.4 Plate assays for the detection of thiaminase secreting bacteria 
Cultures were either streaked directly onto agar plates from glycerol stocks or first 
grown overnight in LB liq-uid medium before streaking.  Plates were incubated at 37oC 
until sufficiently grown (approximately 1-2 days in most cases).  Approximately 8 mL 
soft agar composed of 3 mM thiamin hydrochloride, 6 mM pyridoxine (vitamin B6), 0.5% 
Difco agar noble, and 25 mM Na2HPO4 at 6.5 pH at roughly 37oC was poured onto each 
plate and let solidify.  Plates were then incubated for either 1 hour or 3 hours at 37oC. The 
diazonium reagent reported by Abe et al. was made, and approximately 8.5 mL of the final 
rea-gent was poured onto each plate at room temperature immediately after preparation 
and decanted after 5 minutes.16  p-Acetylphenyldiazonium in the solution re-acts with 
deprotonated 1 as shown in Scheme 3 to produce a purple-red color.  Yellow regions or 
haloes of less intense  purple-red color around colonies than in regions of no growth 
therefore indicated potential thiamin degradation according to literature precedent.  
Absence of any halo indicated no thiamin degradation.  
 
1.4.5 HPLC assay for the detection of thiaminase secreting bacteria 
Cultures were grown from glycerol stocks in 5 mL LB liquid medium overnight at 
37oC in a shaking incubator.  The cultures were then centrifuged at 5,000 rpm and 23oC 
for 5 minutes, decanted, and resuspended in 1 mL M9.  They were again centrifuged, 
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decanted, resuspended in 1 mL M9, centrifuged, and decanted.  The cells were 
resuspended in the minimal volume of M9 necessary to provide 100 μL aliquots for each 
subsequent sample.  100 μL aliquots were transferred to 5 mL liquid M9 medium with 1 
mM MgSO4, 0.1 mM CaCl2, 0.0625 g/mL glucose, 5 mM 2-mercaptoethanol, and 20 mM 
thiamin chloride unless otherwise indicated for approximately 48 hours at 37oC in a 
shaking incubator.  For combinations of individual strains, the strains were grown 
separately in LB and then 100 μL aliquots of each were transferred into the same tube to 
make the combination samples.  After approximately 48 hours incubation, the optical 
density of each sample at 600 nm was recorded and aliquots were centrifuged at 15,000 
rpm and 4oC for 20 minutes.  Su-pernatants were stored at 4oC and then centrifuged after 
thawing at room temperature for an additional 20 minutes at 15,000 rpm and 4oC before 
analysis via HPLC. 
In the HPLC method, the ratio of 100 mM phosphate buffer at pH 6.6 (P) to 
methanol (M)/water mixture was varied over times in minutes (t).  The gradient was car-
ried out following the scheme (t, M%, H2O%, P%): (0, 0, 0, 100), (7, 0, 10, 90), (12, 15, 
25, 60), (22, 65, 25, 10), (25, 0, 0, 100).  The HPLC column was an Agilent Eclipse XDB-
C18 (5μm) 4.6 x 150 mm followed by a diode array detec-tor set to 250 nm for the analysis.  
To normalize cell density, peak areas at 17.8 and 18.8 minutes were obtained from the 
HPLC and divided by respective optical density. 
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CHAPTER II 
MODIFIED SYNTHESIS OF 2’-METHOXYTHIAMIN PYROPHOSPHATE AND ITS 
COMPETENCE IN THIAMIN-DEPENDENT ENZYMES 
 
2.1 Introduction to Bacimethrin 
Bacimethrin (4), a structural analog of the thiamin pyrimidine, is a thiamin 
antagonist first isolated from Bacillus megaterium.31 It exhibits antibiotic activity against 
a variety of yeast and bacteria.32 It acts as a thiamin antagonist due to its conversion to 2’-
methoxythiamin a thiamin analog inside the bacterial cell. Another bacterium 
Streptomyces albus also produces bacimethrin. Bacimethrin was harvested and purified 
from the culture medium of the bacteria suggesting that the compound is secreted outside 
the cell and released into the surrounding environment.33 The toxicity of bacimethrin is 
due to the formation of 2’-methoxythiamin pyrophosphate by the endogenous thiamin 
biosynthetic genes. Due to the structural similarity with thiamin, 2’-methoxythiamin can 
inhibit a subset of essential enzymes that utilizes thiamin pyrophosphate as a cofactor. 
Addition of thiamin into the culture medium completely counteracts the toxicity caused 
by bacimethrin.34 
 
2.1.1 Biosynthesis of bacimethrin 
Cooper et al. identified the biosynthetic gene cluster, and characterized each of the 
enzymes involved in the pathway (Figure 2.1).26 
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Figure 2.1: Organization of genes in bacimethrin biosynthetic operon in C. botulinum A 
ATCC 19397. The genes were annotated based on homology – (3) glycosyltransferase 
(bcmB), (4) thymidylate synthase (bcmA), (5) methyltransferase (bcmC), (6) thiaminase-
I (bcmE), (7) pyrimidine kinase (bcmD) 
 
BcmA is a thymidylate synthase that catalyzes the hydroxymethylation of cytidine-
5’-monophosphate (CMP, 1) using methylene tetrahydrofolate as the co-substrate. BcmB 
is a nucleoside hydrolase that cleaves the N-glycosidic bond of 2 and produces 5-
hydroxymethylcytosine (3). BcmC is a SAM-dependent nucleophilic methyltransferase 
that catalyzes the methylation of C-2 hydroxyl group of 3 to form bacimethrin (4) (Figure 
2.2). BcmD is the bacimethrin pyrophosphokinase that pyrophosphorylates bacimethrin, 
which will then couple with thiazole phosphate inside the cell and can form 2’-
methoxythiamin. 
 
 
 
 
 
 
Figure 2.2: Steps involved in the bacimethrin biosynthetic pathway. The role of each 
enzyme is shown. 
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2.1.2 First reported synthesis of bacimethrin 
Drautz et al. first reported the synthesis of bacimethrin.33 The cyano-HMP (8) was 
prepared by the condensation of O-methyl isourea with ethoxymethylene malononitrile in 
the presence of sodium methoxide as a base (Scheme 2).35 The obtained cyano-HMP was 
then reduced to formyl-HMP (9) using LiAlH4 as a reducing agent. The final step was 
carried out using sodium borohydride for a further reduction of 9 to obtain bacimethrin 
(4). 
 
 
 
 
 
 
 
Scheme 2.1: Synthetic steps of Bacimethrin followed by Drautz et al. 
 
Another synthetic method of 4-amino-5-hydroxymethyl-2-methyl pyrimidine was 
also reported in the literature with little changes in the reduction procedure.36 This method 
can also be a good strategy to be employed for the synthesis of bacimethrin. 
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2.1.3 First reported synthesis of 2’-methoxythiamin 
A synthetic scheme for bacimethrin was later reported in the literature, which was 
further extended to synthesize 2’-methoxythiamin.37-38 The synthesis of cyano-HMP (8) 
was same as the previous method. In the next step, instead of LiAlH4 reduction, a 
Palladium-charcoal catalyzed high pressure (45-50 psi) hydrogenation was performed in 
a Parr apparatus in acidic medium at room temperature for one hour to make the formyl-
HMP (9). However, if the same reaction was continued for three hours bacimethrin was 
formed as the product. A suspension of bacimethrin in THF was treated with diphenyl 
phosphoryl azide in the presence of DBU as a base to form azido-pyrimidine (14). 14 was 
then reduced to aminomethyl-pyrimidine (15) by Palladium-charcoal catalyzed 
hydrogenation at room temperature and pressure. This compound was used to synthesize 
methoxythiamin and the thiazole ring was constructed using a method originally 
developed for thiamin synthesis.39 
 
Scheme 2.2: Steps involved in the synthesis of 5-(aminomethyl)-2-methoxypyrimidin-4-
amine 
 
2.1.4 Enzymatic synthesis of methoxythiamin 
Begley group has also demonstrated the synthesis of methoxythiamin phosphate 
from bacimethrin (4) and 5-hydroxyethyl thiazole (10) using thiamin biosynthetic 
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enzymes ThiD, ThiM, ThiE, and ThiL.34 Bacimethrin (4) was synthesized using the 
reported method and it was pyrophosphorylated to 5 using the thiamin pyrimidine kinase 
ThiD. Similarly, thiazole ethanol (10) was also phosphorylated by ThiM and ATP to give 
11. These two were linked together using ThiE enzyme to form methoxythiamin 
phosphate (12). The formation of thiamin moiety was determined by highly sensitive 
thiochrome assay. A reaction catalyzed by ThiL enzyme converted the monophosphate to 
the methoxythiamin diphosphate (13). 
 
Scheme 2.3: Steps involved in the enzymatic semi-synthesis of 2’-methoxythiamin 
pyrophosphate. 
 
2.2 Results 
2.2.1 Modification of the methoxythiamin synthetic route 
No in vitro experiment has been done yet to study the effect of methoxythiamin 
pyrophosphate on the thiamin-dependent enzymes. A collaboration was established with 
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Jordan research group in Rutgers University, NJ to develop a modified method of 
methoxythiamin synthesis and to study its effect of thiamin dependent enzymes in vitro. 
In this method, mouse thiamin pyrophosphokinase was used for the first time to 
pyrophosphorylate the synthesized compound. 
 
2.2.2 Attempt to synthesize 2’-Methoxythiamin via direct coupling of the pyridine and 
thiazole moieties 
 
 
 
 
Scheme 2.4: Proposed synthetic scheme for the synthesis of methoxythiamin by coupling 
the corresponding pyrimidine bromide with thiazole. 
 
The synthesis of methoxythiamin was originally planned using the coupling 
between the thiazole and the pyrimidine bromide (17). First, bacimethrin (4) was 
synthesized using the procedure reported in the literature.33 of the Several attempts to 
synthesize the pyrimidine bromide (17) was made, however, the methyl aryl ether linkage 
was observed to be very unstable in acidic conditions at high temperature (Scheme 2.4). 
Hydrolysis of the methyl ether during the reaction yielded the hydroxyl pyrimidine. This 
strategy required modification for the successful synthesis of bacimethrin. 
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2.2.3 Modification of aminomethyl-pyridine synthesis 
The synthesis of cyano-HMP (8) was performed following the literature 
procedure.35 The previous synthesis of aminomethyl pyrimidine (15) required four 
synthetic steps after starting with cyano-HMP. An attempt was made to complete the 
synthesis only in one step. Reduction of cyano- pyrimidine by Raney nickel and hydrogen 
in high pressure was previously reported.40 H-Cube continuous flow catalytic 
hydrogenator was used to carry out the reaction in our experiment.  
 
Scheme 2.5: Dimerization of pyrimidine during hydrogenation. 
 
When the reaction was attempted in the absence of liquid ammonia, a new product 
was formed. It was later identified as the dimerized amino pyrimidine (18) (Scheme 2.5).  
The cyano- pyrimidine (8) is first reduced to the corresponding imine which was then 
further reduced to the amine. Not all the molecules are reduced up to the amine at the same 
time. The newly formed amines are now available to react with the imine form inside the 
reactor. As imines are very electrophilic, they undergo nucleophilic addition with the 
amines, followed by elimination of ammonia and a further reduction to form the dimer.  
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Scheme 2.6: Proposed steps involved in the formation of dimerized pyrimidine during 
the reduction of nitrile to an amino group by Raney Nickel-catalyzed hydrogenation. 
 
This issue was later addressed by adding methanolic ammonia solution (7M) to the 
reaction mixture, so that the final concentration of ammonia becomes 1.4M. The 
ammoniacal solution of the 8 was passed through the hydrogenator at 70 oC and 60 bar 
using Raney Nickel as a catalyst.  
 
2.2.4 Complete synthesis of 2’-Methoxythiamin pyrophosphate 
The other precursor, compound 22, was synthesized using little modification to the 
literature described method (Scheme 8B).4 cetyl butyrolactone (20) was chlorinated at 
room temperature using sulfuryl chloride followed by acid catalyzed decarboxylation to 
afford 21 which was further acetylated to produce 22. The intermediate compound 24 was 
prepared by reacting 19 and 22 with carbon disulfide followed by acid catalyzed 
dehydration. The purification of the intermediate 23 was bypassed to avoid potential 
product loss in column chromatography. Oxidation of 24 with acidic hydrogen peroxide 
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affords 2’-methoxythiamin (16). After neutralization, the pH of the solution was adjusted 
to 4.0 and barium chloride was added to isolate the sulfate by-product. 
A) 
 
 
B) 
 
 
C) 
 
 
 
 
 
 
Scheme 2.7: A convergent synthetic route for methoxythiamin pyrophosphate. A) 
Synthesis of the pyrimidine part, B) synthesis of the thiazole precursor and C) coupling of 
4 and 7 to give methoxythiamin (16) followed by enzymatic phosphorylation. 
 
 
Here we also report the first synthesis of methoxythiamin diphosphate from 
methoxythiamin using mouse thiamin pyrophosphokinase (TPK) and ATP. Use of this 
enzyme was reported to produce thiamin pyrophosphate from thiamin in preparative 
scale.41 The reaction was performed with a little modification where instead of the 
potassium bicarbonate buffer (pH - 8.0), potassium phosphate buffer (100 mM, pH – 7.5) 
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was used. High Performance Liquid Chromatography (reverse phase) was used as the tool 
of purification to harvest the compound (13) efficiently (Scheme 8C). 
 
2.2.5 Study on thiamin-dependent enzymes with Methoxythiamin pyrophosphate 
Five thiamin-dependent  enzymes were  studied where  thiamin  diphosphate 
(ThDP)  was replaced by the synthesized 2’-Methoxythiamin pyrophosphate (MeO-
ThDP). These enzymes are pyruvate dehydrogenase complexes from E. coli and human 
(PDHc-ec and PDHc-h), 1-deoxy-D-xylulose-5-phosphate synthase (DXPS) from E. coli 
and 2-oxogluterate dehydrogenase complexes from E. coli and human (OGDHc-ec and 
OGDHc-h). A high percentage of tightly bound thiamin was observed in OGDHc-ec and 
OGDHc-h enzymes, and that could not be replaced by MeO-ThDP. Hence, the major focus 
of the study was on the rest of the three enzymes. MeO-ThDP was found to be a 
functionally competent analog of ThDP. However, it inhibits the activity of thiamin-
dependent enzymes by several folds. Approximately 5.9-11% of NADH production was 
detected with PDHc-ec. This number rises to 48-75% in case of PDHc-h, making it most 
efficient enzyme using MeO-ThDP. 8.8-14% DXP formation was recorded upon 
replacement of ThDP with MeO-ThDP in E. coli DXPS. Jordan research group observed 
that MeO-ThDP binds to the active site of the thiamin-dependent enzyme with binding 
constant similar to that of ThDP. However, the circular dichroism (CD) and fluorescence 
quenching data indicate that the mode of binding is probably different. Our second 
collaborator, Tittmann research group, at Gottingen, Germany, has crystallized 
transketolase with 18 bound at the active site (Unpublished). The structure indicates a 
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steric interaction between the methoxy group of 18 and an active site glutamate 
responsible for the activation of the cofactor.  
 
2.3 Discussion 
Replacement of thiamin by 2’-methoxythiamin pyrophosphate in thiamin-
dependent enzymes could restore a little activity to the enzyme, however, the enzymes are 
inhibited to different extents.13 There can be two possible reasons for the inhibition, steric 
and electronic. Thiamin binds in its signature V-conformation in the active site of all 
thiamin-dependent enzymes.14-15 In this conformation both of the pyrimidine and the 
thiazole ring stays in a way so the pKa of the amino group can modulate the acidity of the 
proton attached to the C-2 of thiazolium. Replacing the methyl with methoxy group in the 
pyrimidine ring adds an extra pair of electrons from the oxygen atom that can be 
delocalized over the ring and can alter the pKa of the amino group. This alteration, in turn, 
affects the catalytic activity. On the other hand, due to the presence of the bigger methoxy 
group the binding mode of the thiamin can be different and the proper conformation of the 
cofactor molecule cannot be retained. This difference will also change the catalytic 
property of the coenzyme and thus will inhibit the enzyme. Methoxythiamin 
pyrophosphate was successfully synthesized and tested on different thiamin-dependent 
enzymes in vitro. The data from Jordan group indicated that methoxythiamin 
pyrophosphate binds to the thiamin-dependent enzymes with a binding affinity similar to 
thiamin but with a different binding mode. The presence of the bulkier methoxy group 
makes it a poorer fit in the enzyme active site. This hypothesis was further reinforced by 
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Tittmann research group who obtained the crystal structure of transketolase, with 
methoxythiamin bound at the active site. The structure showed that there is a steric 
interaction between the methoxy group and the key catalytic glutamate residue. Due to 
this interaction, the glutamate residue cannot be positioned properly with respect to 
thiamin and hence the enzyme is inhibited. This observation ruled out the possibility of 
inhibition due to the change in the electronic properties of the cofactor molecule. 
 
2.4 Experimental 
2.4.1 Overexpression and Purification of Thiamin Pyrophosphokinase 
A plasmid encoding mouse thiamin pyrophosphokinase (TPK) in a pET28a vector 
was transformed into E. coli BL21 (DE3). The gene was overexpressed in LB media at 37 
oC, and the cell lysate was passed through a GE HisTrap HP (5 mL) column. After washing 
with 30 mL wash buffer (100 mM potassium phosphate, 150 mM NaCl, 25 mM Imidazole, 
2 mM TCEP, pH – 7.5) the protein was eluted with 15 mL elution buffer (100 mM 
potassium phosphate, 150 mM NaCl, 250 mM Imidazole, 2 mM TCEP, pH – 7.5). After 
concentration and desalting 3 mL of 1.0 mM purified protein was obtained. 
 
2.4.2 Synthetic procedure 
4-amino-2-methoxypyrimidine-5-carbonitrile (8): Sodium (250 mg, 11 mmol) and o-
methylisourea bisulfate (1.00 g, 5.8 mmol) were added to 30 mL of ethanol and stirred for 
1 hour. The precipitate was filtered, and the filtrate was refluxed for 4 hours with 
ethoxymethylene malononitrile (800 mg, 6.5 mmol). The reaction mixture was stirred at 
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room temperature for an additional 2 hours to give the product as a yellow precipitate. 
This was filtered and purified by column chromatography (10% chloroform-methanol) to 
yield 3 (475 mg, 55%) as a bright yellow solid. 
1H NMR (400 MHz, DMSO d6):  3.84 (3H, s), 8.46 (1H, s) 
13C NMR (100 MHz, DMSO-d6): 54.45, 83.74, 115.62, 163.50, 164.29, 165.94. 
 
5-(aminomethyl)-2-methoxypyrimidin-4-amine (19): Methanolic ammonia (10 mL, 7M) 
was added to a solution of 8 (300 mg, 2 mmol) in 40 mL of methanol. The mixture was 
then passed through a Thalesnano H-cube hydrogenator with Raney Nickel catalyst at 70 
oC and 60 bar hydrogen gas pressure at a flow rate of 0.7 mL/min. The solution was then 
concentrated, and 19 (230 mg, 75%) was purified by column chromatography (25% 
chloroform-methanol) as a pale yellow solid. 
1H NMR (400 MHz, DMSO d6):  3.51 (2H, s), 3.73 (3H, s), 6.79 (2H, s), 7.76 (1H, s) 
13C NMR (100 MHz, DMSO-d6): 39.53, 53.45, 112.15, 154.16, 163.99, 164.22. 
 
3-acetyl-3-chlorodihydrofuran-2(3H)-one (21) Acetyl--butyrolactone 20 (5g. 0.039mol) 
was cooled to -18 oC in a salt-ice bath under a nitrogen atmosphere and sulfuryl chloride 
(5.4g, 0.04 mol) was added dropwise over a period of 1 hr. The reaction mixture was 
warmed to room temperature, stirred overnight, poured onto ice, extracted with ethyl 
acetate and dried over anhydrous Na2SO4. Upon evaporation of the solvent, the crude 
product 21 (5g, 80%) was obtained as a colorless liquid, it was used into the next step 
without further purification. 
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1H NMR (400 MHz, CDCl3):  2.45 (3H, s); 2.61 (1H, m); 3.11 (1H, m); 4.41 (2H, m) 
13C NMR (100 MHz, DMSO-d6) 25.51, 35.20, 66.22, 68.85, 170.48, 198.14 
 
3-chloro-4-oxopentyl acetate (22) Compound 21 (4 g, 24.6 mmol) was added to a mixture 
of glacial acetic acid (4.5 mL),  water (0.7 mL) and concentrated HCl (0.2 mL) and 
refluxed overnight. After cooling to room temperature, acetic anhydride (5g) was added. 
The reaction mixture was then heated at 120 oC for 36 hours. Finally, the reaction mixture 
was diluted with diethyl ether and purified by column chromatography (10% ethyl acetate-
hexane) to give pure 7 (2.77g, 63%) in the form of a pale yellow oil.  
1H NMR (400 MHz, DMSO d6):  1.98 (3H, s), 2.03s (1H, m), 2.26 (1H, m), 2.27 (3H, s), 
4.10 (2H, m), 4.70 (1H, dd, J = 13.76, 3.48 Hz);  
13C NMR (100 MHz, DMSO-d6): 20.47, 26.45, 31.69, 60.16, 60.79, 171.87, 201.72 
 
3-((4-amino-2-methoxypyrimidin-5-yl)methyl)-5-(2-hydroxyethyl)-4-methylthiazole-2 
(3H)-thione (24) In order to synthesize 9 the following components were added in a small 
round-bottomed flask (25 mL); 3.3 mL absolute ethanol, 0.3 mL 20% ammonium 
hydroxide and 0.75 mL water. Compound 4 (300 mg, 1.95 mmol), compound 7 (500 mg, 
2.81 mmol) and carbon disulfide (0.15 mL) were added to it. The reaction mixture was 
stirred at room temperature for 15 hours, and the product 8 was extracted with ethyl acetate 
This product was used in the next step without further purification or characterization. A 
crude mixture of 8 was dissolved in 4 mL 10% HCl and stirred at 80 oC for 20 minutes. 
Upon neutralization with 25% ammonium hydroxide solution the product separated as a 
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precipitate. After filtration and drying, 9 (420 mg, 70%) was isolated as a pale yellow 
solid.  
1H NMR (400 MHz, DMSO d6):  2.08 (3H, s), 2.69 (2H, t, J = 5.94), 3.52 (2H, dd, J = 
17.12, 5.48), 3.74 (3H, s), 5.23 (2H, s), 7.02 (2H, s), 7.42 (1H, s). 
13C NMR (100 MHz, DMSO-d6):  12.46, 29.26, 44.08, 53.59, 60.22, 104.37, 120.44, 
135.84, 154.45, 162.58, 164.55, 185.45 
 
2’-Methoxythiamin (16): Hydrogen peroxide (250 L 30%) was added to a solution of 8 
(310 mg) in 3 mL of 10% HCl. The reaction mixture was stirred on an ice bath for 30 
minutes and then at room temperature for 1 hour. A BaCl2 solution was added to 
precipitate the sulfate ions generated in the previous step. The mixture was filtered. The 
filtrate was evaporated to dryness to yield 252 mg (72%) 2-methoxythiamin chloride 
hydrochloride.  
1H NMR (400 MHz, D2O):  2.67 (3H, s), 3.29 (2H, t, J=5.74 Hz), 3.98 (2H, t, J = 5.76 
Hz), 4.24 (3H, s), 5.61(2H, s), 8.11 (1H, s), 9.70 (1H, s). 13C NMR (100 MHz, D2O) 
 
 
2’-Methoxythiamin pyrophosphate (13) Methoxythiamin hydrochloride 10 (3 mg) and 
ATP (12 mg) were dissolved in potassium phosphate buffer (5 mL, 100 mM, pH-8.0) 
containing MgSO4 (20 mM). Purified thiamin pyrophosphokinase enzyme solution (100 
L, 1.0 mM) was added to the mixture and incubated at 37 oC for 12 hours. 
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Methoxythiamin pyrophosphate 13 was purified by reverse phase HPLC in quantitative 
yield. 
 
2.4.3 High Performance Liquid Chromatography (HPLC) conditions for the isolation 
of 11 
Agilent 1200 series instrument; Supelcosil SPLC-18-DB column (25 cm x 10 mm, 
5 m). The following gradient was used with (A) water, (B) 10 mM ammonium acetate 
and (C) methanol; 0 min, 100% B; 5 min, 10% A/90% B; 9 min, 25% A/60% B/15% C; 
14 min, 25% A/10% B/65% C; 19 min to 25 min, 100% B. 
1H NMR (400 MHz, D2O):  2.69 (3H, s), 3.98 (2H, t, J = 5.38 Hz), 4.04 (3H, s), 4.28 
(2H, dd, J = 17.88 Hz, 6.24 Hz), 5.47 (2H, s), 8.13 (1H, s), 9.42 (1H, s). 13C NMR (100 
MHz, D2O) 11.23, 27.58, 50.93, 54.99, 64.70, 101.18, 135.27, 143.19, 159.51, 164.12, 
165.68, 180.27 
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CHAPTER III 
SYNTHESIS AND BIOCHEMICAL STUDIES ON 13C2,15N3-THIAMIN 
PYROPHOSPHATE 
 
3.1 Introduction 
Pyruvate dehydrogenase complex (PDC) enzyme that catalyzes pyruvic acid 
decarboxylation and acyl group transfer to coenzyme-A uses thiamin pyrophosphate as a 
cofactor. The catalytic mechanism is already known, and it is shown in Figure 3.1.42 All 
the intermediates of thiamin diphosphate in this mechanism are not fully characterized. 
Large size and insolubility of the fully assembled PDC make the study of the mechanism 
intermediates by solution NMR difficult. Crystal structure of this complex is also 
unavailable. To overcome these limitations solid state NMR is emerging as an effective 
technique for structural investigation of these kinds of supramolecular assemblies.43 
Isotopically labeled thiamin diphosphate analogs are reported as probes to study the 
catalytic mechanism in E1 component of PDC by tracking the states of ionization and 
tautomerization of specific bonds in the molecule by solid state NMR spectroscopy.44-45 
13C2 and 15N3 labeled thiamin pyrophosphate (12) was chosen as a probe to investigate 
the intermediate states of thiamin in fully assembled PDC. 2D hetero-correlation NMR 
experiments on 13C-15N will be used as a tool to get atom specific information. 
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Figure 3.1: Mechanism of the reaction catalyzed by PDC enzyme  
Firstly, a strategy has been designed to incorporate labels at the designated 
positions of the thiamin pyrophosphate, and the labeled analog was successfully 
synthesized after. The synthesized molecule was then sent to our collaborator Dr. Kai 
Tittmann in Gottingen, Germany for further biochemical investigations 
 51 
 
 
Figure 3.2: Structure of the thiamin molecule with location of isotopic labeling 
3.2 Results and Discussion 
The target molecule (12) (Figure 3.2) has to be synthesized with the labels at the 
designated positions so a strategy was designed where a proper labeled precursor/ building 
block can be used. The strategy we followed here is making the pyrimidine and the 
thiazole part separate followed by coupling them together to form the thiamin molecule. 
Finally, the synthesized molecule was planned to be phosphorylated enzymatically by 
ATP and thiamin pyrophosphokinase.  
 
3.2.1 Synthesis of the thiazole moiety 
The precursor that was found to be suitable for the synthesis was 13C and 15N 
labeled thiourea. The synthetic strategy was adopted from an old literature method for 
synthesizing 14C lableled thiazole at the C2 of the heterocyclic ring (Scheme 3.1).46 2-
acetyl butyrolactone was reacted with sulfuryl chloride to yield 2-acetyl-2-chloro 
butyrolactone (2). It was then refluxed with acetic acid and hydrochloric acid mixture to 
give 3-chloro-4-oxopentyl acetate (3). After purification, 3 was  dissolved in dry ethanol 
and condensed with 13C and 15N labeled thiourea (4). This condensation product 2-amino-
4-methyl-5--acetoxyethylthaizole (5) which was hydrolyzed to give 6 without further 
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purification. Compound 6 was then purified followed by diazotization and deamination to 
yield the labeled 4-methyl-5--hydroxyethylthaizole (7). This diazotization reaction was 
achieved at -5 oC, using a salt-ice bath. The entire scheme was first optimized with non-
labeled compound and finally the targeted thiamin analog was prepared from 13C and 15N 
labeled precursor. 
 
 
Scheme 3.1: Synthetic scheme for the labeled thiazole part of the molecule. 
3.2.2 Synthesis of the pyrimidine moiety 
 
Scheme 3.2: Synthesis of the pyrimidine part for the coupling reaction. 
The pyrimidine part of the thiamin was designed to assimilate a nucleophilic attack 
by the synthesized thiazole moiety. To carry out this strategy, a chloride group was 
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introduced to the methylene carbon to make it electrophilic (Scheme3.2). Grewe diamine 
(8) was a generous gift from Roche. The amino methyl group of 8 was converted to 
hydroxymethyl by diazotization and hydrolysis.38 This molecule (9) was then treated with 
thionyl chloride and 4-amino-5-chloromethyl-2-methyl pyrimidine (10) was separated as 
a yellow solid.47 
 
3.2.3 Coupling of the pyrimidine and thiazole: Formation of the thiamin 
 
Scheme 3.3: Formation of labeled thiamin by coupling of the electrophilic pyrimidine 
and nucleophilic thiazole  
 
In the final reaction, these two precursor molecules (7 and 10) were mixed with a 
few drops of anhydrous DMSO and heated at 100 oC for 15 minutes (Scheme 3.3). Dilute 
hydrochloric acid was added, and the aqueous phase was filtered and evaporated to yield 
the product. No further purification was required. Splitting of the proton attached to the 
C-2 of thiazolium confirms the presence of the labeling (Figure 3.2). Rapid exchange of 
the C-2 proton with deuterium was observed when the NMR was taken in D2O as the 
solvent. Due to the presence of attached deuterium and 15N atom splitting of the labeled 
13C signal was also observed. 
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Figure 3.2: Proton NMR spectrum of the labeled thiazole.  
 
3.2.4 Enzymatic pyrophosphorylation of labeled thiamin 
 
Scheme 3.4: Enzymatic pyrophosphorylation of thiamin using ATP and Mg2+ ion 
 
The synthesized thiamin was further pyrophosphorylated by the catalysis of 
thiamin pyrophosphokinase (TPK) from a mouse with ATP as the phosphate group donor 
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(Scheme 3.4). His-tagged mouse TPK was cloned into a pET-28b vector and 
overexpressed in E. coli and purified by standard protocol using a nickel-NTA column. 
The protein was eluted and desalted and stored in -80 oC. The synthesized thiamin was 
dissolved in pH 7.5 phosphate buffer and ATP was added up to 3 times of the thiamin 
concentration followed by magnesium sulfate. Finally, the TPK enzyme was added, and 
the mixture was incubated at 37 oC for 12 hours. The final product 11 was purified by 
HPLC, dried under reduced pressure and sent out for the biochemical studies with PDC 
enzyme by Tittmann research group (Figure 3.2). 
 
Figure 3.2: HPLC chromatogram of the enzymatic phosphorylation of isotopically 
labeled thiamin. Formation of TPP was only observed in full reaction. 
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3.3 Conclusion 
A synthetic scheme was designed, tested and optimized by synthesizing thiamin 
pyrophosphate with the unlabeled precursor. The labeled thiamin molecule has been 
successfully synthesized following the optimized scheme using labeled precursor (13C, 
15N labeled thiourea). The synthesized molecule was characterized by NMR and mass 
spectrometry. Finally, it was phosphorylated to get the active form of the cofactor. After 
purification by HPLC, it was sent to the Tittmann research group in Gottingen, Germany 
for enzymatic studies with fully assembled PDC. The solid-state NMR-based intermediate 
analysis is in progress. 
 
3.4 Experimental 
3.4.1 Synthetic procedure 
NMR spectra of the final labeled thiazole and the thiamin were reported. For the 
other intermediates, NMR spectra of the unlabeled compounds were reported.  
3-acetyl-3-chlorodihydrofuran-2(3H)-one (2): Acetyl--butyrolactone 1 (5g. 0.039mol) 
was cooled to -18 oC in a salt-ice bath under a nitrogen atmosphere and sulfuryl chloride 
(5.4g, 0.04 mol) was added dropwise over a period of 1 hr. The reaction mixture was 
warmed to room temperature, stirred overnight, poured onto ice, extracted with ethyl 
acetate and dried over anhydrous Na2SO4. Upon concentration the crude product 6 (5g, 
80%) was obtained as a colorless liquid, it was subjected to the next step without further 
purification. 
1H NMR (400 MHz, CDCl3):  2.45 (3H, s); 2.61 (1H, m); 3.11 (1H, m); 4.41 (2H, m) 
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2-amino-4-methyl-5--hydroxyethylthaizole : 5-Acetoxy-3-chloro-2-pentanone, (3) (350 
mg, 1.96mmole) was added to a solution of 13C, 15N – thiourea (5) (75 mg, 0.96 mmole) 
in ethanol (10 mL). The mixture was stirred under nitrogen and heated to reflux for 27 h, 
then cooled and concentrated in vacuum. The crude reaction mixture was dissolved in 2N 
HCl (5 mL) and stirred at room temperature for 6 hrs. After neutralizing with aqueous 
ammonia, the solvent was removed under reduced pressure, and the product 6 was purified 
by column chromatography (silica gel column 10% methanol in chloroform). Yield 90%. 
Spectral data of the unlabeled compound is reported. 
1H NMR (400 MHz, DMSO-d6):  9.12 (s, 2H), 3.51 (2H, t), 2.65 (2H, t), 2.09 (3H, s) 
 
13C and 15N labeled 4-methyl-5--hydroxyethylthaizole: 2-Amino-4-methyl-5-thiazolyl 
ethyl acetate (7) (100 mg, 0.63 mmole) was dissolved in phosphinic acid (3 mL of 50% 
aqueous solution). This solution was cooled to -5 oC under nitrogen and stirred while 
adding sodium nitrite (50 mg, 0.73 mmole). Effervescence and a color change from bright 
yellow to orange were observed. After 45 minutes the solution was neutralized by aqueous 
ammonia, evaporated to dryness and purified by silica gel column 4% methanol in 
dichloromethane. 
1H NMR (400 MHz, DMSO-d6):  8.72 (1H, dd), 3.72 (2H, t), 2.98 (2H, t), 2.37(3H, d) 
 
4-Amino-5-(hydroxymethyl)-2-methylpyrimidine (HMP, 9). A solution containing 454 mg 
(6.58 mmol) of NaNO2 in 5 mL of water was slowly added, using a dropping funnel, to a 
solution of 1.25 g (5.96 mmol) of Grewe diamineâ dihydrochloride in 12.5 mL of 10% 
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HCl, at 90 °C. The reaction mixture was stirred at that temperature for 5 hours and then 
neutralized to pH 8.0 followed by purification by silica gel column with 15% methanol in 
chloroform. Yield 81%. 
1H NMR (400 MHz, D2O)):  7.99 (1H, s), 4.52 (2H, s), 2.39 (3H, s). 
 
4-Amino-5-(chloromethyl)-2-methylpyrimidine (HMP-Cl, 10) This compound was 
prepared by a modification of the literature procedure.48 A mixture of 4-amino-5-
(hydroxymethyl)- 2-(trifluoromethyl)pyrimidine (550 mg, 3.96 mmol), thionyl chloride 
(0.85 mL, 1.4 g, 11.9 mmol), and 10 mL of chloroform was refluxed with stirring for 3 h. 
The product separated as a yellow solid which was filtered and washed several times with 
anhydrous chloroform and dried under vacuum. This product was used without further 
purification. Yield – 72% 
 
13C and 15N labeled Thiamin Chloride: Both compound 7 (30 mg, 0.21 mmole) and 10 (66 
mg, 0.42 mmole) was mixed with 6 drops of anhydrous DMSO and heated at 100 oC for 
15 - 20 minutes. The reaction mixture was then cooled, and 1N HCL (3 mL) was added 
and stirred for half hour. The mixture was filtered, and the filtrate was evaporated to 
dryness under vacuum. The crude mixture was purified by HPLC to get pure labeled 
thiamin. 36 mg (51%) product was recovered. 
1H NMR D2O: d 8.11 (1H, s), 5.54 (2H, dd), 3.96 (2H, t), 3.26 (2H, t), 2.63 
(3H, d), 2.59 (3H, s) 
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13C and 15N labeled thiamin pyrophosphate (12) 13C and 15N labeled thiamin 10 (3 mg) 
and ATP (12 mg) were dissolved in potassium phosphate buffer (5 mL, 100 mM, pH-8.0) 
containing MgSO4 (20 mM). Purified thiamin pyrophosphokinase enzyme solution (100 
L, 1.0 mM) was added to the mixture and incubated at 37 oC for 12 hours. Thiamin 
pyrophosphate 11 was purified by reverse phase HPLC in quantitative yield. 
 
3.4.2 Overexpression and purification of thiamin pyrophosphokinase 
A plasmid encoding mouse thiamin pyrophosphokinase in a pET28a vector was 
transformed into E. coli BL21 (DE3). The gene was overexpressed in LB media at 37 oC, 
and the cell lysate was passed through a GE HisTrap HP (5 mL) column. After washing 
with 30 mL wash buffer (100 mM potassium phosphate, 150 mM NaCl, 25 mM Imidazole, 
2 mM TCEP, pH – 7.5) the protein was eluted with 15 mL elution buffer (100 mM 
potassium phosphate, 150 mM NaCl, 250 mM Imidazole, 2 mM TCEP, pH – 7.5). After 
concentration and desalting 3 mL of 1.0 mM purified protein was obtained. 
 
3.4.3 High Performance Liquid Chromatography (HPLC) conditions for the isolation 
of 11 
Agilent 1200 series instrument; Supelcosil SPLC-18-DB column (25 cm x 10 mm, 
5 m). The following gradient was used with (A) water, (B) 10 mM ammonium acetate 
and (C) methanol; 0 min, 100% B; 5 min, 10% A/90% B; 9 min, 25% A/60% B/15% C; 
14 min, 25% A/10% B/65% C; 19 min to 25 min, 100% B. 
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CHAPTER IV  
SYNTHETIC STRATEGY OF 18F-LABELED THIAMIN ANALOGS FOR 
PET IMAGING TO STUDY DISTRIBUTION OF THIAMIN IN LIVE 
ANIMALS 
 
4.1 Introduction to PET imaging 
Positron Emission Tomography (PET) is a radiological technique that uses a tracer 
molecule that contains a positron emitting nuclide.49 These tracer molecules are 
biologically relevant molecules or their close chemical analogs that can participate in the 
metabolic processes in the body. Upon administration of the tracer molecule in the living 
animal body, it is distributed in the entire body by general circulatory systems and 
accumulates to those parts and organs where it is mostly utilized. The radionuclide emits 
a positron and that can be detected by an outside detector and a three-dimensional image 
of the region of distribution can be constructed by computerized tomography.50  The 
radionuclides mostly used to prepare tracer molecules are 11C and 18F isotopes. Being very 
small in size the atoms can be incorporated without making big perturbation to the primary 
bio-molecule. The most famous example of PET imaging tracer is the 2-deoxy-2-18F-
glucose, used in cancer detection.51 Glucose is primarily utilized in energy metabolism 
and destined to those places where the rate of metabolism is high. Highly active and energy 
consuming organs like heart and brain usually demand more glucose than other parts of 
the body. In the malignant tumors, consumption of glucose is also higher because of the 
high metabolic rate of uncontrolled growth. Radiolabeled glucose analog easily 
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accumulates in these cancerous tumors and can be easily detected thus making this tracer 
a very efficient tool for cancer detection and diagnosis.52-53 PET imaging is also a very 
important tool to study the distribution of drug molecules after administration.  
Vitamin B1 is a crucial cofactor in all forms of life including humans. It is a long 
asked question how it is distributed in the body and what are the organs where it primarily 
accumulates. To study that we planned to synthesize thiamin analogs as tracer molecules 
that will contain 18F atoms as labeling positron emitting nuclide. 18F has a half-life of 110 
min that enables 18F containing tracers to be studied for a longer period of time compared 
to 11C isotope. Energy generating metabolic process like respiration involves enzymes 
requiring thiamin for their activity thus in the metabolically active tissues like heart, brain 
or leg muscle, a greater concentration of thiamin is expected. Injecting radiolabeled 
thiamin into the body followed by PET scans at different time points will demonstrate 
accumulation of the cofactor in different body parts and organs. Cancer tissues potentially 
possess high thiamin requiring cells to maintain an increased rate of respiration and DNA 
synthesis. Thiamin-dependent enzymes like transketolase, pyruvate dehydrogenase, -
ketoglutarate dehydrogenase are an integral part of these metabolic processes.54-55 
Recombinant thiaminase and thiamin antimetabolite show inhibitory effects on cancer cell 
growth signifying thiamin dependence for proliferation. These observations give rise to 
the possibility of accumulation of increased amount of thiamin in the cancer cells and their 
imaging with 18F-thiamin.  
This suggests that 18F-Thiamin may be used to study the distribution of thiamin in 
the body and as a diagnostic tool for tumor detection. Here we report the development of 
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synthetic strategies for two fluorine labeled thiamin analogs designed for the PET imaging 
study. The radiosynthesis of 18F-thiamin will be done at the designated facility with our 
collaborator at UT Southwestern. The distribution map of thiamin in the body of a living 
animal will then be obtained by PET scanning. 
 
4.2 Results and discussion 
The thiamin analog where the terminal hydroxyl group was replaced by a fluorine 
atom was chosen as the first target molecule due to its ease of synthesis (Figure 4.1). 
 
Figure 4.1: Structure of the targeted deoxy-fluorothiamin. 
 
4.2.1 Initial synthetic strategy 
The molecule was targeted to be prepared by coupling reaction between the 
pyrimidine bromide and thiazole fluoride (3) (Scheme 4.1). 
 
Scheme 4.1: Coupling of pyrimidine bromide and thiazole fluoride to form deoxy 
fluorothiamin 
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Deoxyfluorothiazole (3) has been synthesized from the commercially available 4-
methyl-5-hydroxyethyl thiazole in two simple steps.56 The terminal hydroxyl group of the 
starting material was first converted to a good leaving group like triflate or nosylate 
followed by substitution of that leaving group with fluoride ion (Scheme 4.2). Nosylate  
has been found to be a better option regarding yield, purification, and stability. 
A) 
 
 
B) 
 
 
 
Scheme 4.2: Synthesis of A) triflate and B) nosylate of the thiazole precursor 
 
The fluoride insertion reaction was performed by treating thiazole nosylate with 
potassium fluoride in the presence of potassium ion chelator 2,2,2-Crypand ligand 
(Scheme 4.3). Formation of both substitution and elimination product was observed in a 
ratio of 5:2.57 Using tetrabutyl ammonium fluoride (TBAF) as a reagent the ratio of the 
substitution and elimination products (3 & 8) was increased to 9:1 for the desired 
substitution product. 
The desired fluorothiazole was purified by column chromatography after which it 
was subjected to a coupling reaction with 4-amino-5-bromomethyl-2-methyl pyrimidine 
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in anhydrous DMF at 110 oC (Scheme 4.1). Product 2-fluorothiamin was extracted with 
water, evaporated to dryness followed by characterization with NMR and mass spec 
analysis. 
 
 
 
 
Scheme 4.3: Synthesis of the 4-methyl-5-fluoroethyl thiazole from the corresponding 
nosylate with available 18F precursor potassium fluoride. 
 
Synthesis of the bromo-HMP (2) is conducted by treating HMP (10) with a mixture 
of HBr and acetic acid at 110 oC in a pressure tube (Scheme 4.4).  
 
 
 
 
Scheme 4.4: Steps involved in the synthesis of Bromo-pyrimidine (2) 
 
Finally, the target molecule (1) was prepared via the coupling reaction of 2 and 3 
in anhydrous DMF at 100 oC (Scheme 4.1). As the radioactive 18F isotope has a half-life 
of 110 min, insertion of fluoride at the very end of the synthesis was desirable. However, 
in this strategy, one round of purification is required before the coupling and another after 
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it to get 2-fluorothiamin in the pure form. As all the purification steps are time-consuming, 
another strategy was devised to bypass it.  
 
4.2.2 Second strategy for the synthesis of deoxyfluorothiamin 
 
 
 
 
 
 
 
 
 
Scheme 4.5: Alternative strategy for the synthesis of F-thiamin. 
 
 
The major problem of handling thiamin in an organic environment is the polarity 
of the molecule. It bears a positive charge on it which makes it a cationic highly charged 
species, insoluble in organic solvents. This prevented us from putting the fluoride label 
directly on the thiamin molecule. The closest neutral precursor of thiamin is thiamin 
thiazolone that can be oxidized to thiamin within few minutes. We followed a literature 
method to prepare thiamin thiazolone starting from grewe diamine (9) as one of the 
starting materials.39 The terminal hydroxyl group was converted to tosylate and substituted 
by fluoride using tetrabutyl ammonium fluoride as a reagent. Product formation was also 
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observed when KF and 2,2,2-Crypand were used as the fluorinating agent (Scheme 4.5). 
The reaction mixture was subjected to oxidation without further purification and the final 
compound was purified by HPLC. 
 
4.2.3 Development of synthetic strategy for the second fluoro-thiamin analog 
 
 
 
 
Figure 4.2: Structure of the fluorine- thiamin capable of enzymatic phosphorylation 
 
Deoxy-fluorothiamin has a major drawback that it cannot be phosphorylated by 
thiamin pyrophosphokinase inside the cell. The thiamin pyrophosphokinase converts 
thiamin to the corresponding pyrophosphate, which is utilized in the cells as the active 
cofactor. The inability of phosphorylation of the deoxy-fluorothiamin (1) can lead to its 
efflux from the cells giving an erroneous picture of the distribution of the cofactor in the 
body. Hence, another target molecule (15) was chosen for this purpose with least 
perturbation and having the terminal hydroxyl group intact for phosphorylation (Figure 
4.2). According to this strategy, the thiazole part will be synthesized first, and the fluorine 
will be introduced in the next step. After the fluorothiazole is ready, it will be quickly 
coupled with the corresponding pyrimidine bromide to form the fluorothiamin. As the 
coupling was a very crucial reaction and depends on many factors like solubility, 
temperature and thermal stability of the components, an easy synthetic route was designed 
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to optimize the coupling reaction condition. Another aim was to test the synthesized 
fluorothiamin whether it is accepted by E. coli as a replacement of thiamin. 
Fluorothiazole was synthesized in four steps using 16 as the starting material 
(Scheme 4.6). Compound 16 was first oxidized by OsO4 to form the corresponding vicinal 
diol 17 and N-methyl morpholine N-oxide was used to regenerate the OsO4 as it was 
present in a catalytic amount. After selectively protecting the primary hydroxyl group of 
17 by silyl ether, 18 was treated with DAST to incorporate the fluoride group in place of 
the free hydroxyl group to give 19. Finally, cleavage of the silyl ether linkage of 19 with 
aqueous fluoride led to the final fluorinated thiazole 20.  
 
 
 
 
 
 
 
Scheme 4.6: Synthetic route for 2-fluoro-2-(4-methylthiazol-5-yl)ethan-1-ol for 
biological tests 
 
The coupling reaction was attempted with both chlorinated and brominated 
versions of the pyrimidine part. The coupling reaction with the HMP-bromide (2) 
remained unsuccessful probably due to an excess of acetic acid present in it, so chloro-
HMP (23) was considered as a substitute. It was synthesized by treating 10 with thionyl 
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chloride in chloroform under reflux condition (Scheme 4.7).10  After several attempts, 
coupling with chloro-HMP (23) at 100 oC in the presence of anhydrous DMF was 
successful. The product formation was detected in the mass spec analysis (Figure 4.3). 
However, the corresponding mass of the hydrolyzed product was also detected indicating 
that the fluorine atom is labile and can be replaced with hydroxyl group over time when 
kept as an aqueous solution (Scheme 4.8). The small amount of product was insufficient 
for NMR analysis. 
 
 
 
 
Scheme 4.7: Synthesis of Chloro-pyrimidine and its coupling with 20 to form the final 
thiamin analog (15). 
 
 
 
 
 
 
 
 
Figure 4.3: Mass spec analysis of the coupling reaction detects the presence of the 
fluorothiazole as the major product (283.1028). Hydrolysed product hydroxythiamin was 
also detected  at mass of 281.11 (Scheme 4.8) 
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Scheme 4.8: Hydrolysis of fluorothiamin to dihydroxythiamin 
 
 
4.2.4 Bacterial growth study with fluorothiazole 
Fluorothiazole was used as a supplement to ThiG knock out mutant of E. coli. As 
ThiG is responsible for biosynthesizing the thiazole part of the thiamin molecule, ThiG 
mutant of the bacteria is unable to make the thiazole and has to acquire it from the media 
for survival. The cells were grown in minimal media with 50 M purified fluorothiazole 
and a growth rate similar to the thiamin supplementation was observed. Later it was 
discovered that in aqueous media fluorothiazole is hydrolyzed to dihydroxythiazole (17) 
(Scheme 4.9), however, this experiment suggested that thiazole with a substituent at C2’ 
is a biosynthetically competent analog. Instability of fluorothiazole in the aqueous solution 
closes the option for enzymatic in vitro synthesis of fluorothiamin, by thiamin biosynthetic 
enzymes. 
 
 
 
Scheme 4.9: Hydrolysis of the 2-(4-methylthiazol-5-yl)ethan-1-ol to form 2-fluoro-2-(4-
methylthiazol-5-yl)ethan-1,2-diol in the aqueous growth media. 
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4.2.5 Synthesis of fluorothiazole using fluoride ion as the source of fluorine 
After successfully testing the tolerance of the substituted thiazole, we attempted to 
synthesize fluorothizole using fluoride ion as the nucleophile. Since 18F isotope is only 
available in the form of fluoride and not as DAST, the synthetic method was modified so 
that KF can be used as the source of fluorine for incorporation (Scheme 4.10). In this 
strategy after the protection of the primary hydroxyl group, the secondary hydroxyl group 
was planned to be activated by forming esters like triflate or nosylate. Finally, the good 
leaving group would be substituted by fluoride from KF. 222-kryptoffix. 
 
 
Scheme 4.10: Planned synthesis of 2-fluoro-2-(4-methylthiazol-5-yl)ethan-1-ol 
 
Reaction to synthesize the triflate yielded the corresponding pyridine adduct 
instead of the desired product which was characterized by NMR and mass spectroscopy 
(Scheme 4.11). Attempts to incorporate other leaving groups like tosylate or nosylate also 
remained unsuccessful for this molecule.  
 
Scheme 4.11: Formation of pyridine-thiazole adduct 
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4.3 Challenges and future direction 
We have successfully demonstrated synthesis of one thiamin analog for PET 
imaging study and have shown that the second target molecule (15) is well accepted as a 
cofactor in cellular metabolism. Synthesis of a cyclic sulfate followed by fluoride 
substitution, ring opening and hydrolysis is also a reasonable option for synthesizing the 
fluoro-thiazole (20). A post-doctoral research associate in the lab has proposed another 
synthetic strategy and for fluorothiazole using hydrofluoric acid (HF) as the fluoride 
source (Scheme 4.11-A), although it is not an available form of the 18F isotope. A different 
strategy for the coupling reaction is also proposed (Scheme 4.11-B). Synthesis and 
purification of the fluoro-thiamin analog using the new strategy is currently underway.  
We have collaborated with a research group in UT Southwestern for the PET 
scanning experiments. The hot synthesis of the molecule will be carried out after the 
synthetic route to 15 is optimized and the followed by the PET imaging experiments. 
A) 
 
 
 
 
B) 
 
 
Scheme 4.11: A) Proposed Synthesis of fluorine labeled thiamin using hydrofluoric acid 
as the fluorinating agent. B) Strategy proposed for the coupling of the pyrimidine and the 
thiazole part to give the targeted fluorinated thiamin molecule. 
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Figure 4.4: Structure of the newly designed thiamin analog 
 
To bypass the problem of hydrolysis of the fluoride at the benzylic like positions, 
I have designed the another thiamin analog (Figure 4.4). As it has been observed before 
that methoxythiamin can act as a competent cofactor so we expect effective 
phosphorylation and good binding of (25) in thiamin dependent enzymes. A synthetic 
route is also designed and the synthesis is currently underway. 
 
4.4 Experimental 
4.4.1 Synthetic procedure 
4-Amino-5-(hydroxymethyl)-2-methylpyrimidine (HMP, 9). A solution containing 454 mg 
(6.58 mmol) of NaNO2 in 5 mL of water was slowly added, using a dropping funnel, to a 
solution of 1.25 g (5.96 mmol) of Grewe diamineâ dihydrochloride in 12.5 mL of 10% 
HCl at 90 °C. The reaction mixture was stirred at 90 °C for 5 hours and then neutralized 
to pH 8.0 followed by purification by a silica gel column with 15% methanol in chloroform 
with 81% yield. 
1H NMR (400 MHz, D2O):  7.99 (1H, s), 4.52 (2H, s), 2.39 (3H, s). 
 
5-(bromomethyl)-2-methylpyrimidin-4-amine (2): A 2:1 mixture of glacial acetic acid and 
HBr (3 mL) was added to 250 mg (1.78 mmole) of 10 in a pressure tube. The mixture was 
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heated at 110 oC for 30 minutes with stirring. The compound first dissolves in the solvent 
and forms a clear solution and then after few minutes the product separates as a precipitate. 
It was then filtered and washed with dichloromethane and dried under vacuum. 295 mg 
(1.49 mmole) product was recovered (Yield 83%). The isolated product was used for 
coupling reaction without further purification.  
1H NMR:  
 
4-Amino-5-(chloromethyl)-2-methylpyrimidine (HMP-Cl, 23) This compound was 
prepared using some modification of the literature procedure.48 A mixture of 4-amino-5-
(hydroxymethyl)- 2-(trifluoromethyl)pyrimidine (550 mg, 3.96 mmol), thionyl chloride 
(0.85 mL, 1.4 g, 11.9 mmol), and 10 mL of chloroform was refluxed with stirring for 3 h. 
The product separated as a yellow solid. This was filtered and washed several times with 
anhydrous chloroform and dried under vacuum. This product was used without further 
purification (Yield – 72%).  
1H NMR (400 MHz, DMSO-d6):  8.31 (1H,s), 4.63 (2H, s), 2.39 (3H, s) 
 
2-(4-methylthiazol-5-yl)ethyl trifluoromethanesulfonate (5): To a solution of 4 (500 mg, 
3.5 mmole) in 20 mL anhydrous dichloromethane, trimethylamine (1.78 g, 7.0 mmole) 
was added and stirred at room temperature for 15 min under nitrogen. 4-
Nitrobenzenesulfonyl chloride (1.16 g, 5.25 mmole) was then added to it. The mixture 
was stirred for 4 hours, and the product formation was checked by TLC. After purification 
by column chromatography 648 mg (67%) of 5 was isolated. 
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1H NMR DMSO: 9.39 (1H, s), 3.59 (2H, t), 2.92 (2H, t), 2.36 (3H, s) 
2-(4-methylthiazol-5-yl)ethyl 4-nitrobenzenesulfonate (6): To a solution of 4 (500 mg, 3.5 
mmole) in 20 mL anhydrous dichloromethane trimethylamine (1.78 g, 7.0 mmole) was 
added and stirred at room temperature for 15 min under nitrogen. Triflic anhydride (1.28 
g, 4.55 mmole) was then added to it in a dropwise manner. The mixture was stirred for 6 
hours, and the product formation was checked by TLC. After purification by column 
chromatography 956 mg (83.5%) of 6 was isolated. 
1H NMR (400 MHz, DMSO-d6):  8.76 (1H, s), 8.39 (2H, d), 8.07 (2H, d), 4.30 (2H, t), 
3.13 (2H, t), 2.22 (3H, s) 
 
5-(2-fluoroethyl)-4-methylthiazole (3): To a solution of 6 (110 mg, 0.34 mmole) in 5 mL 
anhydrous acetonitrile KF (43.5 mg, 0.75 mmole) and [2,2,2]-kryptofix (282 mg, 0.75 
mmole) were added and the mixture was stirred at 80 oC for 30 minutes under nitrogen. 
The product 3 (29 mg, 0.2 mmole) was purified by column chromatography (61%). 
1H NMR (400 MHz, DMSO-d6):  8.83 (1H, s), 4.56 (2H, m), 3.15 (2H, m), 2.38 (3H, s) 
 
3-((4-amino-2-methylpyrimidin-5-yl)methyl)-5-(2-hydroxyethyl)-4-methylthiazole-2(3H)-
thione (12): The following components were added in a small round-bottomed flask (25 
mL); 3.3 mL absolute ethanol, 0.5 mL 20% ammonium hydroxide and 0.75 mL water. 
Compound 9 in dihydrochloride form (420 mg, 1.95 mmol) was then added followed by 
3-chloro-4-oxopentyl acetate (500 mg, 2.81 mmol) and carbon disulfide (0.15 mL). The 
reaction mixture was stirred at room temperature for 15 hours, and the product 11 was 
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extracted with ethyl acetate and used in the next step without further purification. A crude 
mixture of 11 was dissolved in 5 mL of 10% HCl and stirred at 80 oC for 20 minutes. Upon 
neutralization with 25% ammonium hydroxide solution the product separated as a 
precipitate. After filtration and drying, 12 (470 mg, 81.5%) was isolated as a pale yellow 
solid.  
1H NMR (400 MHz, DMSO d6):  2.08 (3H, s), 2.28 (3H, s), 2.89 (2H, t,), 3.52 (2H, dd), 
5.23 (2H, s), 7.00 (2H, s), 7.41 (1H, s) 
 
2-(3-((4-amino-2-methylpyrimidin-5-yl)methyl)-4-methyl-2-thioxo-2,3-dihydrothiazol-5-
yl)ethyl 4-methylbenzenesulfonate (13): In a solution of 12 (300 mg, 1.01 mmole) in 
anhydrous pyridine at 0 oC Tosyl chloride (300mg, 1.58 mmole) was added and the 
mixture was stirred for 6 hours. It was allowed to warm to room temperature, and the 
solvent was removed under reduced pressure. The product 13 (380 mg, 85%) was 
recovered after purification by column chromatography. 
1H NMR (400 MHz, DMSO d6):  2.07 (3H, s), 2.29 (3H, s), 2.93 (2H, t,), 4.13 (2H, dd), 
5.18 (2H, s), 7.00 (2H, s), 7.38 (1H, s) 7.43 (2H, d), 7.69 (2H, d). 
 
3-((4-amino-2-methylpyrimidin-5-yl)methyl)-5-(2-fluoroethyl)-4-methylthiazole-2(3H)-
thione (14): 150 mg (0.33 mmole) of the 13 was dissolved in 3mL of 10% MeOH in 
acetonitrile. 175 mg (0.67 mmole) of Tetrabutylammonium fluoride hydrate was added, 
and the reaction mixture was stirred at 75 oC for 25 minutes. 78.6 mg (80%) of 14 was 
isolated after purification by column chromatography. 
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1H NMR (400 MHz, DMSO d6):  2.10 (3H, s), 2.20 (3H, s), 3.00 (2H, m), 4.54 (2H, m), 
5.23 (2H, s), 7.00 (2H, s), 7.39 (1H, s). 
 
3-((4-amino-2-methylpyrimidin-5-yl)methyl)-5-(2-fluoroethyl)-4-methylthiazol-3-ium 
chloride hydrochloride (1): To a solution of 14 (50 mg, 0.17 mmole) in 3 mL 10% HCl, 
150uL of aqueous H2O2 was added. The reaction mixture was stirred at r.t. for 20 minutes, 
and the mixture was then evaporated to dryness under reduced. The product 1 was formed 
in almost quantitative yield. 
1H NMR (400 MHz, D2O):  2.51 (3H, s), 2.63 (3H, s), 3.51 (2H, m), 4.85 (2H, m), 5.66 
(2H, s), 78.10 (1H, s). The proton on C2 of thiazole was not visible due to rapid exchange 
with deuterium. 
 
1-(4-methylthiazol-5-yl)ethane-1,2-diol (17): To a solution of (16) (625 mg, 5.0 mmole) 
in a 1:1 mixture of water and THF (20 mL) a 4% aqueous solution of OsO4 (0.5 mL) was 
added follower by the addition of N-methyl morpholine N-oxide (880 mg, 7.5 mmole). 
The mixture was stirred overnight at room temperature, concentrated under reduced 
pressure and was purified by column chromatography (10% methanol in chloroform) to 
yield 685 g (~86%) of 17 as a white crystalline solid. 
1H NMR (400 MHz, DMSO-d6):  8.74 (1H, s), 4.94 (1H, t), 4.08 (1H, m), 3.70 (2H, m), 
2.33 (3H, s) 
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2-((tert-butyldimethylsilyl)oxy)-1-(4-methylthiazol-5-yl)ethan-1-ol (18): t-Butyl dimethyl 
silyl chloride (950 mg, 6.3 mmole) was added to a solution of 17 (500 mg, 3.14 mmole) 
in 15 mL pyridine. The mixture was stirred under nitrogen for 15 hours, the solvent 
evaporated under vacuum, and the product was purified by column chromatography (20% 
ethyl acetate in hexane). The product 18 (1.1 g, 80.5% yield) was obtained as a colorless 
sticky oil. 
1H NMR (DMSO, 400 MHz):  8.84 (1H, s), 5.73 (1H,d), 4.87 (1H, m), 3.71 (2H, m), 
2.32 (3H, s), 0.80 (9H, s), -0.42 (3H, s), -0.67 (3H, s) 
 
5-(2-((tert-butyldimethylsilyl)oxy)-1-fluoroethyl)-4-methylthiazole (19): To a solution of 
18 (400 mg, 1.45 mmole) in anhydrous dichloromethane (5 mL) at 78 oC, 
Diethylaminosulfur trifluoride (DAST, 0.25 mL) was added drop wise, and the solution 
was warmed to room temperature and stirred for 3 hours. The solution was then again 
cooled to -78 oC and excess unreacted DAST was quenched with methanol (0.3 mL). After 
warming at room temperature, the organic solution was washed with saturated K2CO3 
solution twice followed by drying on Na2SO4 and purification by column chromatography. 
240 mg (60% yield) of 19 was obtained as pale yellow liquid.  
1H NMR (DMSO, 400 MHz): δ 9.02 (1H, s), 5.95 (1H, m), 3.92 (2H, m), 2.41 (3H, d), 
0.89 (9H, s), 0.47 (3H, s), 0.42 (3H, s) 
 
2-fluoro-2-(4-methylthiazol-5-yl)ethan-1-ol  (20): To a solution of 19 (100 mg, 0.36 
mmole) in 5 mL acetonitrile KF(42 mg, 0.72 mmole), Kryptofix-222 (270 mg, 0.72 
 78 
 
mmole) and trimethylsilyl chloride (80 mg, 0.74 mmole) were added and the mixture was 
stirred at 80oC for 20 minutes. Product 20 (33 mg, 57% yield) was purified by 
chromatography on silica column. 
 
4.4.2 High Performance Liquid Chromatography (HPLC) conditions for the isolation 
of 1 
Agilent 1200 series instrument; Supelcosil SPLC-18-DB column (25 cm x 10 mm, 
5 m). The following gradient was used with (A) water, (B) 10 mM ammonium acetate 
and (C) methanol; 0 min, 100% B; 4 min, 8% A/77% B; 8.6 min, 20% A/15% B/65% C; 
17 min, 20% A/15% B/65% C; 20 min to 25 min, 100% B. Flow rate 2 mL/min. 
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CHAPTER V  
EXPLOITING THIAMIN AS A DELIVERY VEHICLE FOR CARGO INSIDE 
LIVING CELL 
 
5.1 Introduction 
The ATP-binding cassette (ABC type) family of transporters in bacteria is one of 
the largest superfamilies of transporters and very well studied for a long time.58-60 The 
ABC transporters for different substrates are very similar in their mechanism of action in 
which a periplasmic substrate-binding protein acts as an initial receptor and the ligand-
bound protein then interacts with a membrane-bound carrier protein stimulating the 
hydrolysis of ATP by the ATPase subunit.61-62 
Thiamin has a specific and dedicated ABC-type transporter that can transport it 
through the cell membrane. In the replete condition of thiamin, the biosynthetic pathway 
in the cell shuts down and it starts to uptake thiamin available in the surroundings, and 
this process is regulated by a riboswitch.63 The transportation of thiamin across the cell 
membrane occurs by active transport by an ABC-type transporter ThiBPQ.64-66In this 
system, ThiB, thiamin binding protein (TBP) is a periplasmic protein and can bind free 
and phosphorylated thiamin, ThiP is the transmembrane protein, and ThiQ is the 
nucleotide binding domain (NBD) that binds the ATP.23, 67 ThiXYZ is another ABC 
transporter for thiamin uptake consisting of ThiY (Substrate binding domain), ThiX 
(Transmembrane domain) and the ThiZ (Nucleotide/ATP binding domain).68-69 This 
transportation system mostly transports the pyrimidine precursor (HMP) of thiamin rather 
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than thiamin itself and co-localized with an HMP kinase encoding gene.70-71 It is involved 
in the thiamin salvage pathway from degraded forms of thiamin present in the soil.25 
There are several anti-bacterial organic compounds that do not have the capability 
of crossing the cell membrane. To deliver these molecules in the cell, a strategy has been 
designed by linking these molecules with cell penetrating peptides (CPP). The cell 
membrane prevents proteins, peptides and drug carriers from entering cells unless an 
active transport mechanism is involved.72 The exact molecular pathway of cellular uptake 
of cargo linked to CPP across the cellular membrane is not fully understood. However, a  
large number of different therapeutic agents have been efficiently delivered by  CPPs.73  
Thiamin and its two phosphorylated forms can bind to the thiamin binding protein and 
transported inside the cell. This suggests that the transporter has high tolerance about the 
moiety attached to the terminal hydroxyl group. Hence, thiamin can be utilized as a vehicle 
to deliver cargo inside the cell. The cargo molecules can be linked with thiamin through 
some cleavable linking functionalities that will enable them to enter the cell with thiamin 
uptake. The linkage will then be cleaved, and the active molecule will be released inside 
the cell.  
Due to the presence of several non-specific esterases we choose carbamate and 
ester functional groups for linking the cargo molecule with thiamin. Here we report the 
development of a synthetic methodology to link cargo molecules with thiamin to be 
delivered inside the bacterial cell. 
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5.2 Results  
5.2.1 Development of synthetic methodology for ester linkage 
As thiamin is a positively charged cationic species, it is completely insoluble in 
aprotic organic solvents. To link the cargo molecule with thiamin, some thiamin precursor 
has to be used that can be easily converted to thiamin. 
 
Figure 5.1: Reaction condition for converting thiamin thiazolone to thiamin. 
 
Thiamin thiazolone (1) could be an option for this purpose, but it should undergo 
oxidation under acidic condition to give thiamin (Figure 5.1). As both ester and carbamate 
linkages are acid labile, this strategy could not be used. 
 
 
 
 
 
 
Figure 5.2: Reduction of the disulfide bond of thiamin disulfide to produce thiamin 
 
Thiamin disulfide was chosen as the neutral thiamin precursor to load the cargo. It 
can be easily converted to thiamin in the presence of a reducing agent like DTT, 2-
mercaptoethanol or TCEP (Figure 5.2). These reagents do not harm the ester or carbamate 
linkage between thiamin and the cargo molecule. 
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Ester linkage can be used for any molecule that has a carboxylic acid group, where 
they can be linked with the free hydroxyl group of the thiamin molecule. In this strategy, 
the carboxylic acid group is activated by N,N′-Dicyclohexylcarbodiimide (DCC) in the 
presence of a base and then the thiamin precursor is added to the reaction mixture to form 
the linkage. 
Such reaction is quite common in organic chemistry and previously reported.74 
However, we chose DMF as the solvent because of poor solubility of thiamin disulfide in 
all other solvents. Indole-3-acetic acid was chosen as the example cargo molecule to 
establish the synthetic viability of this process. 
The reaction was carried out at room temperature where a solution of DCC in 
anhydrous DMF was added to an equimolar mixture of thiamin disulfide (3) and indole-
3-acetic acid (4) in the same solvent (Scheme 5.1). After 19 hours of stirring the compound 
was purified by column chromatography and reduced by TCEP to yield the final ester 
linked adduct of thiamin and indole-3-acetic acid (6). 
 
 
 
 
 
 
 
Scheme 5.1: Linking cargo molecule with thiamin by an ester linkage. 
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5.2.2 Formation of carbamate linkage 
Patel et al. reported formation of a carbamate linkage between thiamin and amine-
functionalized nanoparticle.75 Unsuccessful attempts to reproduce the same strategy 
forced us to investigate newer possibilities. First two attempts of activating the thiamin 
hydroxyl group by carbonyldiimidazole (CDI) (7) in short time have failed.76-77 Finally, 
successful activation was done by stirring the reaction mixture for 18 hours which was 
confirmed by formation of carbamate linkage by isopropyl amine (9) (Scheme 5.2).78 
The thiamin disulfide - isopropyl amine adduct (10) was purified by column 
chromatography and the NMR was recorded. Finally the target compound (11) was 
prepared by treating 10 with a solution of TCEP. 
 
 
 
 
 
 
 
 
 
 
Scheme 5.2: Formation of carbamate linkage with thiamin for amine group containing 
cargo. 
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This protocol was explored with the methyl ester of alanine, and a clean mass of 
the adduct was obtained. Successful demonstration of this methodology was applied to 
form adduct between thiamin and ampicillin (Figure 5.3). 
 
 
 
.  
 
 
 
 
Figure 5.3: Mass spectra (+ve mode) of the thiamin alanine methyl ester adduct and 
thiamin-ampicillin adduct 
 
We then planned to explore this strategy to deliver alanine phosphonate into the 
cells, and a synthetic route was optimized to synthesize the Ala-P molecule. Ala-P is an 
inhibitor for alanine racemase and thus can act as antibiotic. It cannot be transported 
directly into the bacterial cell and needs a carrier for delivery. 
 
 
 
 
Figure 5.4: Structure of the Ala-P molecule. 
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5.2.3 Synthesis of (1-aminoethyl)phosphonic acid (Ala-P) and thiamin-Ala-P conjugate 
The targeted molecule (Ala-P) was attempted to be made from acetyl chloride (12), 
trimethoxy phosphine, and hydroxyl amine. After the condensation reaction, the hydroxyl 
imine (14) was planned to be reduced by catalytic hydrogenation (Scheme 5.3).79 
 
 
 
Scheme 5.3: Attempt to synthesize dimethyl ester of Ala-P 
 
The hydroxyl amine (14) was successfully prepared, however, the reduction 
reaction by catalytic hydrogenation with H2 and Raney nickel gave a complex mixture of 
compound that could not be purified. To bypass the reduction reaction by hydrogenation 
the synthetic strategy was revised (Scheme 5.4). Benzyl carbamate was chosen as the 
source of nitrogen for Ala-P. Oxidation state of the central carbon precursor was also 
modified from +3 (Acetyl chloride) to +2.  
 
 
 
Scheme 5.4: Synthesis of (1-aminoethyl) phosphonic acid avoiding the reduction step 
 
 
First benzyl carbamate was condensed with acetaldehyde to form 16. A Michael-
type 1,4 addition of trimethyl phosphite across the imine linkage gave 17. Hydrolysis of 
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17 with dilute hydrochloric acid yielded the desired Ala-P (18).80 The product obtained 
was in hydrochloride form.  
The product 18 was found to be insoluble in DMF and hence the attempt of the 
carbamate adduct formation with thiamin was unsuccessful. Neutralization of 
hydrochloride of Ala-P by methanolic ammonia followed by evaporation of the solvent 
did not increase the solubility. In the next attempt, the molecule was neutralized by 
tetrabutyl ammonium hydroxide with the hope that presence of a counter ion with large 
hydrophobic side chain would increase the solubility. However, the carbamate forming 
reaction was still unsuccessful. 
The strategy was further changed to overcome this problem. As the phosphonate 
esters can be selectively cleaved by trimethyl silyl bromide we attempted to make Ala-P 
phosphonate ester, link it to thiamin disulfide followed by deprotection and ring closure 
(Scheme 5.5).81  The amine group of Ala-P was first protected by trifluoroacetyl group 
followed by esterification of the phosphonic acid by ethyl orthoformate to give 19. The 
triflate group was removed by treatment of sodium borohydride in ethanol (Scheme 5.5).82 
The resulting compound (20) was purified and characterized by NMR. 
 
 
 
Scheme 5.5: Strategy for the Synthesis of diethyl (1-aminoethyl)phosphonate. 
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The phenyl ester of Ala-P was prepared to modify the existing protocol (Scheme 
5.6).83 However, attempt to couple any of the esters (20 and 22) with thiamin disulfide 
was unsuccessful. 
 
 
 
 
 
 
Scheme 5.6: Synthetic scheme for the preparation of diphenyl ester of Alanine 
phosphonate. 
 
5.3 Conclusion and future directions 
A strategy has been successfully designed to deliver cargo molecules inside the 
cell using thiamin as a delivery vehicle. Ester and carbamate linkages were used as the 
coupling functionality. Synthetic routes has been optimized to develop a methodology that 
can be used for a wide variety of cargo molecules. Synthesis of the Thiamin – Ala-P 
conjugate is currently underway. To avoid the solubility problem, possibility of the 
synthesis of the carbamate linkage in the water containing media will be explored. After 
the synthesis, the molecule will be tested for antibacterial activity. To ensure the delivery 
inside the cell a radiolabeled cargo molecule will be used in future. 
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5.4 Experimental 
5.4.1 Synthetic methods 
The chemicals were purchased from Sigma-Aldrich.  
 
5-(2-(2-(1H-indol-3-yl)acetoxy)ethyl)-3-((4-amino-2-methylpyrimidin-5-yl)methyl)-4-
methylthiazol-3-ium (6): Thiamin disulfide (562 mg, 1 mmol), indole-3-acetic acid (175 
mg, 1 mmol) and DMAP (146 mg, 1.2 mmol) was dissolved in anhydrous DMF (10 mL) 
and stirred for 15 min. DCC (310 m, 1.5 mmol) was added and stirred at room temperature 
for 19 hours. After removing DMF, the intermediate was purified by column 
chromatography and dissolved in water followed by the addition of TCEP (315mg, 1.1 
mmol). The final product (77 %) was characterized by NMR and mass spectroscopy. 
1H NMR: 9.32 (1H, s), 7.83 (1H, s), 7.57 (1H, d), 7.49 (1H, d), 7.39 (1H, s), 7.27 (1H, t), 
7.13 (1H, t), 5.38 (2H, s), 4.45 (2H, t), 3.92 (2H, s), 3.28 (2H, t), 2.69 (3H,s), 2.37 (3H, s) 
 
(3Z,3'Z)-disulfanediylbis(4-(N-((4-amino-2-methylpyrimidin-5-yl)methyl)formamido) 
pent-3-ene-3,1-diyl) bis(isopropylcarbamate) (10): Thiamin disulfide (562 mg, 1 mmol) 
and 1,1′-Carbonyldiimidazole ( 243 mg, 1.5 mmol) were taken in anhydrous DMF and 
stirred at room temperature for 19 hours under inert atmosphere. Isopropyl amine (120 
mg, 2 mmol) was added, and the mixture was stirred for another 18 hours. DMF was 
removed under reduced pressure, and the product was purified by silica column with a 
linear gradient from 5% - 20% methanol in chloroform. Fractions containing the pure 
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product were pooled and recovered by evaporating the solvent in a rotary evaporator. 70% 
product yield was recorded. 
1H NMR: 7.83 (1H, s), 7.94 (1H, s), 6.72 (2H, s), 4.35 (2H, s), 3.90 (2H, m) 3.58 (1H, m), 
2.47 (2H, t), 2.29 (3H, s), 1.96 (3H, s) 1.04 (6H, d)  
 
3-((4-amino-2-methylpyrimidin-5-yl)methyl)-5-(2-((isopropylcarbamoyl)oxy)ethyl)-4-
methylthiazol-3-ium (11): Compound 10 (220 mg, 0.3 mmol) was dissolved in water (2 
mL), and TCEP (95 mg, 0.33 mol) was added and stirred at room temperature for 10 
minutes. The product was purified by HPLC and characterized by 1H NMR, UV-Vis, and 
mass spectrometry. 
1H NMR: 8.86, (1H, s); 8.09 (1H, s); 5.64 (2H, s); 4.41 (2H, t); 3.73 (1H, m); 3.41 (2H, 
t); 2.69 (3H, s); 2.64 (3H, s); 1.17 (6H, d) 
 
dimethyl (Z)-(1-(hydroxyimino)ethyl)phosphonate (14): Acetyl chloride (155 mg, 2 mmol) 
was dissolved in 10 ml of toluene and placed in the flask (50 ml). The mixture was cooled 
to 0 °C, and trimethyl phosphonate (4 mmol, 420 mg) was added very slowly with stirring 
so that the temperature does not exceed 7–8 °C. The mixture was left for a night, and after 
the volatile components were removed under reduced pressure. To the remained crude 
mixture, hydroxylamine hydrochloride (2 mmol, 140 mg), dissolved in 3 ml methanol 
containing pyridine (160 mg, 2 mmol), was added. The mixture was stirred overnight, and 
the solvent was removed under reduced pressure and acidified by 2M HCL 20 mL. The 
product was extracted with ethylacetate (15 mL x 3), dried over anhydrous sodium sulfate 
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and recovered by remolval of the solvent to yield the desired -oxymephosphonate. It was 
characterized by NMR, desired splitting due to the presence of phosphorous was observed. 
1H NMR: 3.73 (1H, d), 3.68 (6H, d), 1.43 (3H, d) 
 
benzyl (1-(dimethoxyphosphoryl)ethyl)carbamate (17): To a well-stirred mixture of 
benzyl carbamate (151 mg, 1 mmol) and trimethyl phosphite (125 mg, 1 mmol) in 3 mL 
AcOH : H2O (1:1), Acetaldehyde (65 mg, 1.5 mmol) was added slowly. The temperature 
was maintained at 85 oC for 2 hrs. The solvent was evaporated under reduced pressure and 
purified by column chromatography. 
1H NMR : 7.32 (5H, m), 4.95 (2H, s), 3.92 (1H, m), 3.65 (6H, d) 1.24 (3H, dd) 
 
(1-aminoethyl)phosphonic acid (18): Compound 17 was refluxed in HCl in methanol (5 
mL) for 15 min. The product was recovered by evaporation of the solvent under reduced 
pressure. Hydrolysis reaction gave a quantitative product yield. 
1H NMR: 3.65 (1H, m), 1.20 (3H, dd) 
 
Diethyl-1-aminoethyl)phosphonate (20): The 1-aminomethylphosphonic acid hydro-
chloride (18) (161 mg, 1 mmol) was dissolved in TFA (0.1 mL) – TFAA (0.6 mL) mixture 
and heated at 50 oC for 15 min. Ttiethyl orthoformate (5 mL) was slowly added and the 
resulting mixture was heated at 110 oC for 2 hours followed by evaporation of the solvent 
giving crude derivative 19. This compound was then dissolved in ethanol (10 mL), sodium 
borohydride (228 mg, 6 mmol) was added and the mixture was stirred at r.t. for 1 hr 
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followed by reflux for 30 min at 80 oC. The volatile components were removed under 
reduced pressure and the residue was dissolved in chloroform and washed with 1M 
aqueous NaHCO3 followed by brine. The chloroform was then evaporated and the crude 
product was purified via column chromatography (20 % Ethyl acetate in hexane). 
1H NMR (CDCl3, 400 MHz), : δ 8.5 (2H, s), 4.45 (1H, m), 4.13 (4H, m), 1.44 (3H, m), 
1.32 (6H, m) 
 
Diphenyl-1-aminoethyl)phosphonate (22): To a mixture of triphenyl phosphite (310 mg, 
1 mmol) and benzyl carbamate (151 mg, 1 mmol) in glacial acetic acid 3 mL acetaldehyde 
(65 mg, 1.5 mmol) was added slowly and the reaction mixture was stirred at room 
temperature for 2 hours followed by heating at 85 oC for two hours. The volatile 
components were removed under reduced pressure to yield the crude product 21 that was 
purified via column chromatography (10 % Ethyl acetate in hexane). This was further 
hydrolyzed by treatment with a solution of 33% HBr in acetic acid at room temperature 
for one hour followed by solvent evaporation and neutralization of the mixture by a 
solution of ammonia in etanol. The final compound (60% overall yield) was also purified 
by column chromatography (15% ethyl acetate in hexane). 
1H NMR (DMSO, 400 MHz), : δ 7.30 (6H, m), 7.13 (4H, m), 4.19 (1H, m), 1.35 (3H, m) 
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CHAPTER VI  
ESTIMATION OF THIAMIN QUOTA IN THE HAPTOPHYTES THAT 
PREFERENTIALLY USE PYRIMIDINE COMPOUNDS TO FULFILL THIAMIN 
REQUIREMENT 
 
6.1 Introduction 
6.1.1 Thiamin biosynthesis and phytoplankton 
Thiamin is an important cofactor in all forms of life and it is biosynthesized in 
most of the bacteria, archaea, fungi and plants. Thiamin biosynthesis requires a certain set 
of genes encoding all of the biosynthetic enzymes that are required to synthesize thiamin 
de novo. In recent studies, by a complete genome analysis of marine taxa, it has been 
observed that the complete canonical thiamin biosynthetic pathway is absent in multiple 
eukaryotic phytoplankton groups.84-85 This observation suggests that in marine ecology 
thiamin auxotrophy is common in producers which in turn indicates a regulatory function 
of thiamin.86-88 Recently three phytoplankton species and a heterotrophic bacterial group 
have been identified that fulfill their thiamin requirement through uptake of 4-amino-5-
hydroxymethyl-2-methylpyrimidine (HMP), an intermediate precursor compound in 
thiamin biosynthesis. This observation perfectly agrees with the absence of key thiamin 
pyrimidine biosynthetic genes in these organisms. Though most of the thiamin auxotrophy 
studies were carried out by supplementing with thiamin alone, reports exist where 4-
amino-5-aminomethyl-2-methylpyrimidine (AmMP), a functional analog of HMP, was 
taken up by thiamin auxotrophic algae.89 Moreover, widespread bacterial oligotroph 
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Pelagibacter ubique (SAR11) can use only AmMP and not exogenous thiamin. This 
indicates that the strategy for thiamin cycling in marine taxa is complex as recently 
reported for B12 analogs in cyanobacteria and eukaryotic algae.
90 
The complete genome sequence was available for approximately 20 such 
phytoplankton species, but most of them are thiamin prototrophs. However, In ocean 
ecosystems the haptophytes are extremely diverse and are the important primary 
producers, which are thiamin auxotroph too.91-94 Among these haptophytes, genome 
sequence was available for Emiliania huxley and Chrysochromulina tobin.95-96  
 
 
 
 
 
 
 
Figure 6.1: Biosynthetic pathway of thiamin pyrophosphate in bacteria 
 
Canonical biosynthesis of thiamin involves two major intermediates that are 
independently biosynthesized, HMP and 4-ethyl-5-b-hydroxyethylthaizole (HET) as 
corresponding phosphates (5 and 7). 5 was biosynthesized from 1-deoxyxylulose-5-
phosphate, tyrosine and cysteine with ThiG, ThiG, ThiO and ThiS proteins, and 7 was 
biosynthesized from AIR (4) by ThiC and ThiD enzymes. Finally, these two precursors 
are coupled together by ThiE to generate thiamin monophosphate (8) by ThiE enzyme 
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(Figure 6.1).97 Subsequent phosphorylation gives the biologically active form of the 
cofactor (9). In some organisms, another pathway exists in parallel that involves 
remodeling of pyrimidine compounds to generate HMP via a salvage pathway.98 The key 
enzyme in the salvage pathway is TenA that catalyzes the formation of HMP from thiamin 
degradation products.98-99  
 
6.1.2 Thiamin quota: why it is important  
Thiamin cellular quotas are also not known for oceanic phytoplankton. Only data 
for thiamin quantification is available for prototrophic phytoplankton isolated from 
brackish water.100 Hence the estimations of thiamin quotas in marine phytoplankton are 
based on calculations and not experiments. For a better understanding of thiamin quotas 
inside the cells, the efficacy of the method has to be evaluated, and these quotas in different 
growth phase have to be determined. Direct measurement of thiamin quotas in cultures of 
thiamin auxotrophic haptophyte in different physiological states is essential to set the 
correct parameters for ecological models in future. 
Our collaborator, Warren research group in Monterey Bay Aquarium Research 
Institute, had identified and compared thiamin biosynthetic pathways from transcriptomes 
sequenced in all six haptophyte orders as well as the available haptophyte genome 
sequences.101-102 Apart from the absence of the HMP synthase in all six orders, the thiamin 
biosynthetic pathway apparently looks complete. Moreover, thiamin thiazole synthase 
(ThiG) is observed to be present in all six order as thiazole synthase, which is 
evolutionarily ancient compared to the eukaryotic analog, Thi4. The first analysis of 
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salvage pathway of thiamin pyrimidine was performed in this study which revealed the 
presence of the TenA gene subfamily in all six haptophyte orders. Haptophytes were 
grown in different concentrations of thiamin and HMP, and the cellular thiamin quotas 
were measured. 
 
6.2 Results and discussion 
6.2.1 Optimization of the thiochrome assay 
Thiochrome assay was used to measure the amount of thiamin present in the 
phytoplankton cells grown in different conditions. Thiamin can be converted to a highly 
fluorescent compound called thiochrome upon oxidation by ferricyanide in alkaline 
medium (Scheme 6.1). This compound is detectable in low nanomolar quantities by 
fluorescence spectroscopy. 
 
Scheme 6.1: Formation of thiochrome from thiamin by potassium ferricyanide in alkaline 
medium 
 
 
One problem encountered with this technique was that some thiamin was being 
detected even in the absence of any sample or exogenous thiamin. This was due to the 
presence of thiamin in the water that was being used for making the reagent solutions. 
This issue was addressed by treating the deionized water with active charcoal under 
stirring conditions for 15 hours followed by centrifugation and sterile filtration. As active 
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charcoal can absorb most of the organic compounds, internal thiamin content of water was 
almost completely removed and was not detected any further by thiochrome assay (Figure 
6.2). 
 
Figure 6.2: Comparison of blank experiments before and after treatment of the water with 
active charcoal. The thiochrome peak disappears after the treatment. 
 
6.2.2 Growth conditions of the haptophyte cells in the laboratory 
E. huxleyi, a member of the haptophyte order, was used to quantify thiamin at the 
cellular level. Cells were grown in different concentrations of thiamin and HMP, and the 
growth rate was measured. The total number of cells in the culture was also counted. 
Thiamin concentration of 300 nM was used as luxury supply. This concentration is about 
15000 times of the maximum reported quantity reported in the habitat zone of E huxleyi 
at the Sargasso Sea, it is used as one of the standard concentrations used in the growth 
media. 10 nM thiamin was chosen as the replete, but the non-luxury concentration in E. 
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huxleyi growth media, five hundred-fold greater than the maximum observed in the 
Sargasso Sea. The growth rate in these two conditions did not differ significantly (0.74 ± 
0.05 day-1 in luxury and 0.71 ± 0.04 day-1 in replete). HMP (6) of the same concentration 
was also used as a growth supplement for E huxleyi. The limiting condition of thiamin 
and HMP was chosen as 0.5 nM, which is more comparable to the concentrations reported 
in the field.103-104 The growth rate was found to be much slower in this condition (0.21 ± 
0.11 day-1).  
 
6.2.3 Estimation of the thiamin content in the haptophyte cells by thiochrome assay 
After the growth of E. huxleyi in the designated media, the cells were harvested 
and washed with thiamin-free media for multiple times. The cells were then stored frozen 
at -80 oC until subsequent analysis of thiamin content in them. For the analysis, the cells 
were thawed and resuspended in 7% perchloric acid (HClO4). The suspension was then 
sonicated to break open the cells and vortexed vigorously to dissolve all the thiamin in the 
solution. An alkaline solution of potassium ferricyanide (K3[Fe(CN)6]) was then added to 
it followed by waiting for 2 minutes and neutralization with hydrochloric acid to pH 7.0. 
The precipitate was discarded by centrifugation, and the supernatant was analyzed by 
HPLC, equipped with a fluorescence detector, to detect thiamin in its different states of 
phosphorylation (monophosphate and pyrophosphate) (Figure 6.3).  
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Figure 6.3: Typical chromatogram of the thiochrome assay mixture performed on an E. 
huxleyi cell lysate. 
 
  
It has been observed that thiamin is primarily stored in the cells as thiamin 
pyrophosphate (9). The thiamin monophosphate (TMP) (8) and free thiamin (TF) (10) is 
present in lesser quantity compared to TPP. The same pattern was also observed when E. 
coli was used as a test sample (data not shown). The amount of different forms of thiamin 
was determined from a standard calibration curve prepared under same experimental 
conditions.The results of this experiment is represented by the following table.  
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Table 6.1. Measured cellular quotas for thiamin pyrophosphate (TPP), thiamin 
monophosphate (TMP), and free thiamin (ThF) in E. huxleyi CCMP2090. Error 
represents the s.d. of three independent measurements and are shown in parentheses. 
 
 
 
The data can also be presented as histogram plot for clear understanding where the 
thiamin quotas in the cells can be visually compared by the plot. 
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Figure 6.4: Cellular quota of thiamin in E. huxleyi cells grown in luxury (300 nM), replete 
(10 nM) and limited (0.5 nM) concentrations of Thiamin and HMP. Data represents 
average of three independent measurements. 
 
 
A very high cellular thiamin quota in the cells grown in luxury thiamin supply 
indicates that a very high storage of thiamin occurs under the conditions of high 
availability. In replete conditions, the thiamin storage was six-fold less than the luxury 
condition. Interestingly, there was not much difference in the thiamin quota for the cells 
grown under replete or limiting the availability of thiamin or HMP as supplements (Figure 
6.4). Previous thiamin measurement data reported in the literature found free thiamin to 
be the dominant intracellular form which is in complete contrast to the results of this 
study.100 The higher thiamin storage in the cells in luxury thiamin availability has little 
environmental relevance. 
The direct measurements of cellular thiamin quotas using thiochrome assay 
enabled us to evaluate the efficacy of the established procedure for calculating minimum 
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cellular quota (MCQ). A large discrepancy was observed between the calculated MCQ 
values and those quantified using the thiochrome assay. The direct measurement results 
indicate that calculated MCQ overestimates the cellular content of thiamin and do not 
accurately represent the biochemical status of the cell. The measured MCQ in the HMP 
amended media was also found to be significantly lower than the calculated value. This 
observation provides essential information for more accurate parameterization of marine 
biogeochemical models for examining the role of thiamin-related compounds in primary 
production. 
 
6.3 Experimental 
6.3.1 Growth of E. huxleyi in laboratory 
Axenic culture of E. huxleyi was obtained from the National Center for Marine 
Algae and Microbiota (NCMA, Bigelow Laboratory, USA). Axenicity was tested before 
and after the experiments using DNA stain 4’,6-diamidino-2-phenylindole (DAPI) and 
epifluorescence spectroscopy.105 All cultures were grown at 21 oC on a 14:10 hr light:dark 
cycle (150 mol photon m-2 s-1 photosynthetically active radiation) using artificial 
seawater based medium L1 – Si, with a 1x10-8 mol L-1 H2SeO3 amendment.106-107 Cultures 
were monitored using an Accuri C6 cytometer (BD Biosciences, USA). Thiamin (as 
Thiamin hydrochloride, Sigma-Aldrich, USA), 4-methyl-5--hydroxyethylthiazole 
(Sigma-Aldrich, USA), 4-methyl-5-hydroxymethyl-2-methyl pyrimidine (HMP) 
(synthesized), were used as supplements for growth.38 Thiamin was not added to controls 
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or treatments apart from the thiamin-amendment, other medium components remained 
unaltered from the L1. 
The cellular thiamin quotas were determined in mid-exponential phase cells grown 
for >10 generations in semi-continuous batch cultures. Four conditions of thiamin 
availability were tested. Thiamin was supplied at 300 nmol L-1 in the luxury treatment. In 
replete conditions both thiamin and HMP were supplied at 10 nmol L-1. In limiting 
conditions thiamin and HMP were supplied at 500 pmol L-1 and 100 pmol L-1 respectively. 
Concentrations in the limiting conditions were different to generate cultures with 
comparable growth rate. Cultures were transferred after 1 to 2 days so that the cell density 
cannot exceed 1 x 106 cells mL-1.  
Thiamin quotas were also quantified in the cells harvested at the onset of the 
stationary phase to replicate the condition of the cells used for calculation based estimates. 
In these experiments, triplicate cultures were grown in medium amended with 500 pmol 
of thiamin or HMP. 
 
6.2.2 Sample preparation for thiamin estimation 
For the thiamin estimation, 100 mL of culture was first centrifuged at 4000 x g for 
10 min at 4 oC.  The supernatant was removed, and the pellet was resuspended in 50 mL 
of thiamin-free media. This process was repeated for total 3 rounds of washing. Following 
the last washing step, the pellet was resuspended in 1.5 mL of thiamin-free medium, and 
the cell concentration was quantified using Accuri C6 cytometer (BD Biosciences, USA). 
A final cell pellet was formed by centrifugation at 10,000 x g for 30 min at 4 oC, the 
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supernatant was removed (and cells quantified), and the cell pellet was flash-frozen in 
liquid nitrogen before being stored a -80 oC. The residual number of the cells in the 
supernatant was subtracted from the number prior to final centrifugation to determine 
numbers in the pellets.  
 
6.3.3 Thiochrome assay and determination of thiamin content in the cell pellets 
Deionized water was treated with active charcoal followed by filtration and 
confirmed to be thiamin-free by thiochrome assay.108 All the reagent solutions were 
prepared using this water. Harvested cell pellets were suspended in 100 L of 7% 
perchloric acid (HClO4), sonicated for 2 min. To this sonicated mixture, 4 M potassium 
acetate (50 L) and 30 mg/mL potassium ferricyanide (K3Fe(CN)6) solution in 7M NaOH 
(50 L) was added and mixed well by vortexing. After incubating for 2 minutes at room 
temperature, the reaction mixture was neutralized to pH 7.0 with 6M hydrochloric acid 
(HCl). The mixture was centrifuged, and the supernatant was analyzed by HPLC (Agilent 
1200 series) using reverse phase column. The HPLC was equipped with a fluorescence 
detector and the thiochrome formed was detected by fluorescence (excitation 365 nm, 
emission 444 nm). 
A calibration curve in the nanomolar concentration range was constructed under 
the same experimental conditions by plotting the fluorescence signal peak area on the 
HPLC chromatogram against known concentrations of thiamin pyrophosphate (TPP), 
thiamine monophosphate (TMP), and free thiamin (ThF). The values of the three forms 
were summed to determine the pool, T Sum, hereafter referred to as thiamin quota.  
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6.3.4 HPLC condition 
A Supelcosil SPLC-18-DB (25 cm x 10 mm, 5 m) column was used with a 
gradient of the following compounds. A) H20, B) K2HPO4 (pH 6.6), C) CH3OH. The 
gradient structure was 0 min, 100% B; 5 min, 100% B; 14 min, 7% A/70% B/23% C; 25 
min, 25% A/75% C; 28 min to 34 min, 100% B.  
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CHAPTER VII  
SUMMARY OF RESULTS OF PRELEMINARY STUDIES ON MJ0619, A 
PUTATIVE METHANOPTERIN METHYLTRANSFERASE  
 
7.1 Introduction 
7.1.1 Methanopterin and its role in methane biogenesis 
Methanopterin (MPT) (1) and its derivatives are key cofactors in the 
methanogenesis process of the methanogenic archaea (Figure 7.1).109-112 It acts as a one-
carbon carrier in the biosynthesis of methane. Methanopterin shares high structural and 
functional similarity with folic acid (2) which is the C1 carrier in several important 
biological reactions in all domains of life and the tetrahydro form is the active form for 
both cofactors (Figure 2).109, 113 Methanogenic archaea use MPT exclusively for 
metabolism, however, methylotrophic archaea use MPT for C1 energy metabolism and 
folate for biosynthesis of other metabolites (Figure 7.2).111 The absence of homology 
between the corresponding biosynthetic enzymes of methanopterin and folate indicates 
that these cofactors evolved independently.114 The enzymes that use folate or MPT as 
cofactors are also not homologous, which reinforces the idea of the independent 
evolution.115  
 
 
 
 
 106 
 
A) 
 
 
B) 
 
 
Figure 7.1: Chemical structure of A) Methanopterin and B) Folic Acid  
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2: Schematic diagram of steps involved in methanogenesis. 
 
7.1.2 Biosynthesis of methanopterin: Origin of the methyl groups 
The presence of the two methyl groups at C-7 and C-9 of the pterin ring 
distinguishes methanopterin from the other pterin-based cofactors (Figure 1). Many steps 
 107 
 
of the biosynthesis of methanopterin are worked out, however, the source of the two 
unique methyl groups on the pterin moiety remained an unsolved question (Figure 7.3).116-
120 In earlier reports, studies with CD3 labeled methionine indicated that it is the source of 
the two methyl groups in the MPT in methanogens. The insertion of the methyl groups 
was proposed to be catalyzed via SAM-dependent nucleophilic methylation.121-123 
However, no such methyltransferases in the methanogenic archaeal genome can be 
identified that are associated with the biosynthesis of MPT and the possibility of radical 
based methylation was therefore considered. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.3: Biochemical steps involved in Methanopterin biosynthesis.  
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7.1.3 Introduction to radical-SAM enzymes 
The recently discovered radical SAM superfamily contains thousands of members 
that catalyze novel biochemical transformations involved in the biosynthesis of cofactors, 
antibiotics, and other natural products.124-127 Several examples of radical SAM-based 
methylation are also reported in the literature.128 Most radical SAM enzymes contain a 
canonical CX3CX2C sequence motif that harbors a 4Fe-4S cubane cluster.
127, 129 Three 
cysteine residues ligate to three iron atoms and S-adenosyl methionine (SAM) acts as the 
ligand of the fourth iron (Figure 7.4).130. The chemistry of these enzymes is initiated by 
one electron transfer from the reduced cluster to SAM followed by homolytic cleavage of 
SAM to generate 5’-deoxyadenosyl radical (Ado-CH2 .). Ado-CH2 · then abstracts a 
hydrogen atom from the substrate of the enzyme to generate substrate based radical that 
undergoes further transformations to yield the product.126 Modified protein residues in an 
enzyme can also be a site for radical formation, thus can act as a co-substrate.131 Reactions 
after radical formation may lead to various results, such as methylation (RlmN in 
methylation of nucleotides), methyl-thiolation (MiaB in t-RNA methyl-thiolation), 
complex rearrangements (ThiC in thiamin biosynthesis, NosL in noshiheptide 
biosynthesis) and even sulfur insertion (BioB in biotin biosynthesis).132-136 
 
 
 
 
Figure 7.4: Schematic diagram of 4Fe-4S cluster in a radical SAM enzyme. Three iron 
atoms are ligated by three cysteine residues and the fourth free iron atom binds the SAM 
molecule during the catalytic cycle. 
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7.1.4 Discovery of MJ0619, putative methanopterin methyltransferase 
Robert White’s research group in Virginia Polytechnic identified a gene (MJ0619) 
that is present very close to another MPT biosynthetic gene, beta-
ribofuranosylaminobenzene-5-phosphate synthase, in many methanogens. This enzyme 
was considered as the putative methyltransferase for the pterin moiety in MPT.137 
Sequence analysis showed that it contains two canonical CX3CX2C motifs, characteristic 
of a radical SAM enzyme. The formation of the methylated pterin moieties was observed 
upon heterologous expression of that gene in E. coli. Previously it was hypothesized that 
the methylations of the pterin moiety in methanopterin biosynthesis happen in one of the 
final steps of the biosynthesis, however, in E. coli the final biosynthetic intermediates of 
MPT are unavailable. Hence, 7,8-dihydro-6-hydroxymethylpterin (3) was proposed as the 
possible substrate of MJ0619. No intermediate monomethylated product (5) was detected 
with the wild-type enzyme suggesting consecutive insertion of both the methyl groups 
(Figure 2). A mutant study by White group observed monomethylation at C-7 with C77A 
mutant and no methylation with C102 mutant (Figure 7.5). Kylie et al. interpreted that the 
cluster bound at the C102 containing motif (CL-2) does the first methylation at C-7 to 
form 5 and the cluster bound at C77 containing motif (CL-1)  catalyzes the second 
methylation at C-9 to form 4 as the final product. If the first methylation does not take 
pace, the second methylation reaction also cannot happen which makes the C102A mutant 
inactive.   
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Figure 7.5: Proposed reactions catalyzed by MJ0619 by Allen et al. A) Reaction proposed 
for wild-type enzyme, B) proposed reaction catalyzed by C77A mutant and C) no 
methylation observed with C102A mutant of MJ0619. 
 
Expression of MJ0619 in E. coli grown with CD3-acetate as the carbon source 
revealed incorporation of all three deuterium atoms in most of the methylated pterin 
formed. Methylenetetrahydrofolate was hypothesized as the probable methyl donor in the 
proposed mechanism to rationalize the isotopic labeling pattern.137 Participation of 
methylenetetrahydrofolate as a methyl donor involving radical-based chemistry is 
unprecedented. Our initial hypothesis of the formation of a substrate-based radical led to 
the initial mechanistic proposal involving SAM or a modified amino acid residue as the 
source of the two methyl groups (Figure 7.6). 
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Figure 7.6: Initial proposal for methylation of the pterin moiety. ‘X’ group denotes the 
methyl carrier. 
 
In this chapter, we report preliminary studies on the in vitro analysis of MJ0619 
enzyme to characterize its spectroscopic properties, GTP cyclohydrolase activity and 
radical activity. 
 
7.2 Results 
7.2.1 Sequence analysis of MJ0619 
The sequence of the MJ0619 protein is given below.  
MEKKTLSLCPICLKRIPATILEEDGKIIIKKTCPEHGEFKDIYWGDAELYKKFDKY
EFIGKIEVTNTKVKNGCPYDCGLCPNHKSTTILANIDVTNRCNLNCPICFANANK
SGKVYEPSFEDIKRMMENLRKEIPPTPAIQFAGGEPTVRSDLPELIKLARDMGFL
HVQLATNGIKLKNINYLKKLKEAGLSTIYLQFDGISEKPYLVARGKNLLPIKQKV
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IENCKKVGFDSVVLVPTLVRGVNDNEVGGIIRYAAENVDVVRGINFQPVSFTGR
VDEKTLLEGRITIPDFIKLVEEQTDGEITEEDFYPVPSVAPISVLVEKLTNDRKPTL
SSHQHCGTSTYVFVDEDGKLIPITRFIDVEGFLEIVKEKIEEIGKSKMHDVKVLGE
IALKLPSLIDLDKAPKSVNIKKIIDLILSVLKSDYSALAELHYHMLMISCMHFMDA
YNFDVKRVMRCCIHYATPDDRIIPFCTYNTLHRQEVEEKFSIPLEEWKRMHKIG
GEDDREDY 
MJ0619 has a molecular weight of 57.5 kDa and it has an unusually high cysteine 
content of 15 residues per monomer. Cysteine residues are coded in bold red. In addition 
to these two canonical motifs ([C73-C77-C80] and [C98-C102-C105]), two more cluster-
binding motifs are predicted at the N- terminal [C9-C12-C33] and the C-terminal [C438-C455-
C470] of the protein. 
 
7.2.2 Overexpression and purification of MJ0619 
The gene encoding MJ0619 was obtained by custom gene synthesis. It was codon 
optimized for expression in E. coli. The gene was cloned into the pTHT vector, a modified 
pET-28a vector with an additional site for cleavage of the N-terminal His-tag by the 
protease from tobacco etch virus (TEV). The plasmid containing the MJ0619 gene was 
transformed into E. coli BL21-(DE3) cells containing a plasmid with the SUF operon for 
overproduction and delivery of 4Fe-4S clusters to the overexpressing protein. The cells 
were grown in LB broth at 37 oC till OD600 – 0.6 and the protein production was induced 
by addition of Isopropyl β-D-1-thiogalactopyranoside (IPTG), with a supplement of 
Ammonium Iron (II) sulfate hexahydrate [(NH4)2Fe(SO4)
2·6H2O] and cysteine, at 15 oC 
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for 18 hours with gentle shaking. After harvesting by centrifugation, the cells were stored 
in liquid nitrogen until purification.  
The frozen cells were thawed on ice and resuspended in 100 mM Tris buffer (pH 
– 7.5) in an anaerobic chamber. Lysozyme and benzonase nuclease were added to degrade 
the cell wall and the RNA in the cell. These cells were then lysed by sonication, 
centrifuged to remove the cell debris and the supernatant was passed through a freshly 
charged Ni-NTA His-Trap column. The flow through from the column was discarded and 
the bound protein was washed with 100 mL of buffer containing 30 mM imidazole to get 
rid of any non-specifically bound protein. Finally, the protein was eluted with 250 mM 
imidazole buffer, the colored fractions were pooled and concentrated and buffer 
exchanged with storage buffer containing 30% glycerol. Purity of the protein was 
determined by analysis through an SDS-PAGE (Figure 7.7) gel electrophoresis and the 
protein concentration was determined by Bradford assay. 
 
 
 
 
 
 
 
Figure 7.7: SDS-PAGE gel of MJ0619 protein after purification. 
 
MJ0619 
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7.2.3 Reconstitution of the 4Fe-4S cluster in the purified MJ0619 
Initial estimation of the iron and sulfur content of the as isolated protein showed 
that the number of iron and sulfur atoms per monomer is half of the calculated amount. In 
vitro reconstitution is thus necessary to maximize the 4Fe-4S cluster content of the protein. 
For reconstitution of 4Fe-4S cluster in MJ0619, the purified protein was dissolved in 
PIPES buffer (50 mM, pH – 7.4) and cooled on ice for 30 min in a Coy anaerobic chamber. 
Solutions of Mohr’s salt [(NH4)2Fe(SO4)2·6H2O] and sodium sulfide (Na2S.9H2O) were 
added in small portions over 45 minutes up to the final concentration of 10 times greater 
than that of the protein. The mixture was incubated on ice for six hours and then the 
precipitated iron sulfide was removed by centrifugation. The protein was again desalted 
to remove excess unbound iron and sulfide and then stored in the same buffer. 
 
7.2.4 Measurement of iron and sulfur content in MJ0619 
There are fifteen cysteine residues present in the protein sequence along with two 
canonical CX3CX2C motifs. The protein was likely to contain at least two 4Fe-4S clusters, 
however, more clusters can be expected harbored by other cysteine residues. Ferrozine 
assay was used to measure the iron content and protein concentration was measured by 
Bradford assay. It has been observed that in as isolated protein, there are ~5 iron and sulfur 
atoms per monomer, however, in the reconstituted protein the number rises to ~15 iron 
and sulfur per monomer indicating the presence of at least three to the maximum of four 
4Fe-4S clusters. This hypothesis is later confirmed by the data from EPR experiments. 
Possibility of non-specifically bound iron and sulfide ions are also considered. 
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7.2.5 Construction of the mutants 
There are two CX3CX2C motifs present in the protein. They are C73-X3-C77-X2-
C80 (CL-1) and C98-X3-C102-X2-C105 (CL-2). Multiple alignments of MJ0619 with its 
orthologs have also revealed that these two canonical motifs along with two other non-
canonical motifs are conserved.  It has been proposed that both of them are catalytically 
active and each can cleave one SAM molecule to generate 5’-deoxyadenosyl radical. 
Three mutants were constructed via the standard protocol of single point mutagenesis. In 
the first two mutants cysteines of the individual motifs were mutated to alanine (M1 and 
M2) and in the third mutant cysteines of both the motifs were converted into alanine (M3) 
(Table 7.1). 
 
Table 7.1: Details of the MJ0619 mutants 
 
Mutant Name Residues modified Mutated to 
M1 C73, C77, C80 All to alanine 
M2 C98, C102, C105 All to Alanine 
M3 C73, C77, C80, C98, 
C102, C105 
All to Alanine 
 
7.2.6 Spectroscopic analysis of the wild-type protein and the mutants 
The wild-type protein MJ0619 and its mutants were analyzed by UV spectroscopy. 
All of them were observed to have a band at 418 nm and one band at 615 nm (Figure 7.8). 
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The presence of the 418 nm band suggests the presence of a 4Fe-4S cluster and the 615 
nm band might be an indication of a 2Fe-2S cluster or non-specifically bound iron.138-139  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.8: UV-Vis spectra of MJ0619 and its mutants. Spectra of A) the wild-type 
protein, B) M1 mutant, C) M2 mutant and D) M3 mutant. All of them have an absorption 
band at 418 nm characteristic of 4Fe-4S cluster. The band at ~ 615 nm may be due to a 
2Fe-2S cluster or non-specifically bound iron in the protein. 
 
A 
B 
C D 
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The 4Fe-4S cluster band at 418 nm is present in the mutant where both the 
canonical cluster binding motifs are mutated clearly indicates that there are at least one 
more 4Fe-4S clusters present in the protein.140 Putative sites for additional cluster binding 
are C9-X2-C12-X20-C33 and C438-X16-C455-X14-C470. 
Upon treatment with dithionite, the band at 418 nm is absent suggesting that all 
the 4Fe-4S clusters present in the enzyme can be reduced by dithionite (Figure 7.9). Some 
of the clusters were stable even when the protein was exposed to air for few hours. It 
retains its brown color and the band at 418 nm was still visible. 
 
Figure 7.9: UV-Vis spectra of reduced and oxidized cluster. Loss of 418 nm band 
observed upon reduction. 
 
7.2.7 EPR analysis of the wild-type MJ0619 and mutants 
The EPR study of the wild type protein and all three mutants revealed that there 
are signals for two types of clusters with g values ~2.01 and ~2.06 indicating the presence 
of two types of 4Fe-4S clusters in the protein (Figure 7.10). The EPR band at 2.01 was 
found to be absent in the M3 mutant suggesting that it contains a cluster different from the 
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ones bound at the canonical CX3CX2C motifs. No EPR band at g = 1.94, representing a 
2Fe-2S cluster, was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10: EPR spectra of A) Wild-type MJ0619, B) M1 mutant, C) M2 Mutant and D) 
M3 mutant. Two EPR bands are visible in the wild type, M1 and M2, however, in M3, 
only one EPR signal was observed. 
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7.2.8 Homolytic cleavage of SAM by MJ0619: Proof of radical generation 
 
 
 
 
Scheme 7.4: 5’-deoxyadenosyl radical is generated upon transferring one electron from 
the reduced cluster to SAM molecule. This radical abstracts a hydrogen atom to from 5’-
deoxyadenosine. 
 
 
A radical SAM enzyme can cleave SAM (11) reductively in anaerobic conditions 
in the presence of a reducing agent to produce 5’-deoxyadenosine radical (12) (Scheme 
7.4). To test the activity of cleaving SAM reductively, MJ0619 was incubated with SAM 
(1.3 mM) and dithionite (5mM) inside the glovebox. As the enzyme is from M. jannaschii, 
a thermophilic organism, the reaction mixture was heated at 70 oC for 20 minutes. 
Although the protein is from a thermophilic organism, it was not stable at that temperature 
and it is denatured and precipitated out within five minutes of incubation. After removal 
of the protein, the reaction mixture was analyzed by HPLC (Figure 7.11). Formation of 
5’-deoxyadenosine was confirmed by comparing the retention time and UV spectrum with 
a commercial standard of the compound. LCMS analysis also confirms the compound’s 
identity by obtaining the exact mass (M+1 = 252.1091) in the acceptable error range. 
Observation through both analytical methods and thereby proves that MJ0619 can cleave 
SAM reductively by one electron transfer and therefore can be categorized as radical SAM 
enzyme.  
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Figure 7.11: HPLC chromatogram of substrate uncoupled 5’-deoxyadenosine formation. 
No product formation in the absence of SAM or MJ0619 enzyme. Little amount of the 
product formation is observed in the absence of dithionite due to the presence of some 
reduced clusters. 
 
7.2.9 Optimization of reaction condition at 37 oC 
SAM is a temperature sensitive molecule and gradually degrades at a higher 
temperature (70 oC). The MJ0619 enzyme is also unstable at that temperature and 
denatures in a very short period of time. This shorter time period might not be sufficient 
for the radical reaction to happen. Many radical SAM enzymes from thermophilic 
organisms show activity at room temperature, so MJ0619 was also incubated at room 
temperature with SAM and dithionite. However, no 5’-deoxyadenosine formation was 
observed. Next trial was done at 37 oC that is the optimal growth temperature of E. coli. 
After incubation of 24 hours uncoupled formation of 5’-deoxyadenosine was observed in 
the amount comparable with that obtained at 70 oC. This condition was chosen to carry 
out the future reactions. 
When the same reaction was tried with the mutant enzymes, it was observed that 
only M1 mutant could produce 5’-deoxyadenosine but either of the M2 and M3 mutant 
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cannot. Hence it was inferred that the second cluster (CL-2) is responsible for the reductive 
cleavage of SAM in the presence of dithionite. 
  
7.2.10 Generation of 5’deoxyadenosine with Flavodoxin (FldA) / Flavodoxin reductase 
(FldR) system 
Being successful at 5’-deoxyadenosine formation at 37 oC, an attempt was made 
to test the FldA / FldR system as reducing agent instead of dithionite. In the physiological 
condition in E. coli cells, this is the actual system of reduction for 4Fe-4S cluster of the 
enzyme. Flavodoxin and flavodoxin reductase are cloned individually into pET-28a vector 
and overexpressed in LB media after transformed into E. coli BL21-DE3 cells. The protein 
overexpression was induced by IPTG (0.5 mM), and it was purified by regular protocol 
with a Ni-NTA His-Trap column from GE. SDS page gel was run to check the purity of 
the protein and the concentrations were measured (Figure 7.12). 
 
 
 
 
 
 
 
Figure 7.12: SDS-PAGE gel analysis of the purified FldA and FldR. Molecular weights 
match with the reported values. 
Flavodoxin 
reductase (FldR) Flavodoxin (FldA) 
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The in vitro reaction was carried out in 100 mM Tris buffer, pH – 7.5, SAM 1.5 
mM, NADPH 1.5 mM and FldA 50 M, FldR 50 M and MJ0619 enzyme ~100 M. The 
reaction mixture was incubated at 37oC for 24 hours, enzymes were heat denatured, and 
the filtrate was analyzed by LCMS after removal of enzymes. Formation of 5’-
deoxyadenosine was observed in the full reaction. Formation of a very small amount of 
5’-deoxyadenosine in the absence of NADPH is due to the presence of pre-reduced 
clusters in the MJ0619 enzyme (Figure 7.13). This experiment confirms that the enzyme 
is active under the physiological conditions in E. coli cell. The efficiency of 5’-
deoxyadenosine formation is 10 fold less compared to dithionite. 
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Figure 7.13: A) Formation of 5’-deoxyadenosine in the presence of FldA / FldR as 
catalysts and NADPH as reducing agent.. B) The exact mass of 5’-deoxyadenosine 
confirms the identity of the compound. 
 
7.2.11 Assay with GTP, discovery of GTP cyclohydrolase activity 
Some orthologs of MJ0619 protein, obtained by BLAST search, were annotated as 
putative MoaA like proteins. MoaA is involved in the biosynthesis of the molybdopterin 
cofactor and uses GTP as substrate, hence GTP was tried as a substrate for MJ0619 with 
SAM and dithionite. Two new peaks in the chromatogram were observed with UV-Vis 
spectra indicating the presence of 7,8-dihydropterin moiety (Figure 7.14). Upon treatment, 
with CIP the first peak disappears and gives neopterin which indicates that it is a 
phosphorylated form of neopterin. The other peak has same UV spectrum as neopterin and 
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the mass corresponds to the mass of neopterin cyclic phosphate (Scheme 7.5). It also 
agrees with the literature data that neopterin cyclic phosphate cannot be cleaved by regular 
phosphatase enzyme.  
 
 
 
 
Scheme 7.5: The reaction of GTP cyclohydrolase: conversion of GTP to 7,8-
dihydroneropterin-2’,3’-cyclic phosphodiester 
 
 
 
 
 
 
 
Figure 7.14: A) Reaction product of MJ0619 with GTP before and after CIP treatment. 
(I) Neopterin triphosphate, (II) Dihydroneopterin phosphodiester and (III) 
dihydroneopterin. B) UV-Vis spectra of neopterin cyclic phosphate.  
 
We prepared an authentic sample of dihydroneopterin cyclic phosphodiester (7) 
by treating GTP with the dedicated GTP cyclohydrolase enzyme (MptA) involved in the 
methanopterin biosynthetic pathway. The coelution experiment confirmed the identity of 
the compound (Figure 7.15). No methylated neopterin was observed. Neither SAM nor 
dithionite is essential for the cyclohydrolase activity. The addition of Mn2+ or Fe2+ ion 
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increases the activity by three fold. Studying different preps of the enzyme it was observed 
that the enzyme always gives less than one turnover in neopterin cyclic phosphate 
formation. 
 
 
 
 
 
 
  
 
 
 
 
Figure 7.15: A) Coelution experiment (gray trace) of neopterin cyclic phosphate 
generated by MJ0619 (blue trace) with an authentic sample of the dihydroneopterin cyclic 
phosphate prepared from GTP and MptA (orange trace). B) Coelution of 7 shown by the 
extracted ion chromatogram of in LCMS analysis, C) MS-MS spectrum of 7 in negative 
mode (exact mass 316.0452). 
 
7.2.12 The linear triphosphate is the precursor of the cyclic phosphodiester of dihydro 
neopterin 
A mesophilic ortholog of MJ0619 from Methanobrevibacter smithii was obtained 
by gene synthesis and used to study the time dependence of the cyclohydrolase reaction. 
It was observed that the amount of the linear phosphate was higher than the cyclic analog 
A B 
C 
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at early time points, however, over time the amount of the linear phosphate decreased, and 
that of the cyclic phosphate had increased (Figure 7.16). This observation clearly suggests 
that dihydroneopterin triphosphate was formed first and later it was converted to the 
corrresponding cyclic phosphodiester.  
This reaction mechanism differs a little from the mechanism proposed for the 
dedicated GTP cyclohydrolase MptA involved in methanopterin biosynthesis where 7 is 
the only product. Two phosphate groups depart and the cyclic phosphate forms right at the 
beginning of the reaction mechanism proposed for MptA,8 however in the case of MJ0619, 
the linear triphosphate (15) is formed first and then it cyclizes to form the cyclic 
phosphodiester (Scheme 7.6). 
The GTP cyclohydrolase activity of MJ0619 is lower at a lower temperature and 
maximizes at 70 oC. M-1 and M-2 mutants of MJ0619 also shows the cyclohydrolase 
activity. Only one turnover is observed and the reason is still unknown. If the reaction time 
is extended up to 24 hours, complete dephosphorylation of the 7,8-dihydroneopterin cyclic 
phosphate is observed and 7,8-dihydroneopterin appears as the final product.  
 
 
 
 
Scheme 7.6: Proposed mechanism of GTP cyclohydrolase activity by MJ0619 
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Figure 7.16: Time course of GTP cyclohydrolase activity of MJ0619 ortholog. 7,8-
dihydroneopterin triphosphate (15) (retention time 1.7 min) was the first product to be 
formed which later converted to 7 (retention time 2.8 min). 
 
7.2.13 4Fe-4S clusters are necessary for cyclohydrolase activity 
The cyclohydrolase activity demonstrated by MJ0619 is a cluster dependent 
activity. When the iron-sulfur cluster is present, the enzyme shows the activity, however, 
when the enzyme is expressed without added iron and cysteine and purified aerobically 
the protein was found to be inactive towards GTP cyclohydrolase activity, as the clusters 
could not be formed (Figure 7.17). 
This observation suggests that presence of the clusters is essential for the 
cyclohydrolase activity by MJ0619, which, in turn, indicates that the cyclohydrolase 
activity is not due to any contaminant copurified with the protein. 
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Figure 7.17: Assay for GTP cyclohydrolase activity with the MJ0619 protein in the 
presence and the absence of bound 4Fe-4S clusters. In the absence of the cluster, the 
protein was found to be inactive.  
 
7.2.14 Phosphatase and nucleosidase activity by MJ0619 
While GTP was incubated with the MJ0619 at 37 oC for 12 hours, two new peaks 
were observed in the chromatogram that has same UV-Vis spectra with GTP. This 
similarity in the spectra clearly indicates that those two compounds contain the guanine 
moiety (Figure 7.18). Later they were identified as guanine and guanosine by comparing 
with the standards. This observation indicates to the phosphatase and nucleosidase activity 
of MJ0619 enzyme (Scheme 7.7). When the assay was conducted in a glove box with 
anaerobically purified enzyme complete substrate consumption along with the formation 
of 7,8-dihydroneopterin cyclic phosphate, guanosine and guanine were observed. 
However, the aerobically purified enzyme devoid of any iron-sulfur cluster showed only 
a little phosphatase activity and all other two activities were absent. The data suggests that 
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the phosphatase activity is not dependent on the presence of the bound Fe-S clusters in the 
enzyme, however, the clusters are essential for the nucleoside hydrolase activity. 
 
 
Figure 7.18: Comparison of GTP cyclohydrolase, phosphatase and nucleoside hydrolase 
activity of MJ0619. In absence of the 4Fe-4S cluster, the enzyme retains its phosphatase 
activity, however, the nucleosidase activity was lost. 
 
 
 
 
 
 
Scheme 7.7: Dephosphorylation and N-glycosidic bond cleavage of GTP by MJ0619. 
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7.2.15 MJ0619 shows nucleosidase activity on variety of nucleosides 
The mesophilic ortholog of MJ0619 from M. smithii was tested for nucleosidase 
activity with a variety of nucleosides to look for whether it can cleave other nucleosides 
as well to generate the nuclear base and ribose sugar (Figure 7.19). The same experiment 
with the cluster free aerobic version of the protein was also performed to test the 
importance of 4Fe-4S clusters in this process. The active anaerobic enzyme was found to 
be active in cleaving the C-N bond between the nucleobase and the sugar, however, the 
aerobically purified protein was found to be inactive. 
A very slow reaction rate was observed when 5’-deoxyadenosine was tested as a 
substrate for the nucleosidase activity. Only a little of the substrate was converted into 
product and most of the starting material remained unreacted in 24 hours. This information 
indicates that the 5’-hydroxyl group is probably necessary for the tight binding of the 
substrate in the active site. 
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Figure 7.19: HPLC chromatogram of the assay of MJ0619 with a variety of purine and 
pyrimidine-based nucleosides. HPLC traces: No enzyme control (blue), Reaction with 
aerobic protein (maroon) and reaction with anaerobic protein (green). The nucleoside 
hydrolase activity was only observed with the anaerobically purified protein. 
 
7.2.16 Assay with 7,8-dihydro-6-hydroxymethylpterin 
Commercially available 7,8-dihydro-6-hydroxymethylpterin was incubated with 
MJ0619, SAM and dithionite at 37oC for 24 hours. The enzyme was heat denatured, 
filtered and the filtrate was analyzed by LCMS. In two preps of enzyme, formation of a 
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peak in the mass-spec was observed that has the same mass and retention time as the 7,8-
dihydro-7,9-dimethyl-6-hydroxymethylpterin (Figure 7.20). 
 
 
 
 
 
 
Figure 7.20: LCMS analysis of the reaction of MJ0619 with 7,8-dihydro-6-
hydroxymethyl pterin as substrate. Formation of a peak at the same retention time and 
exact molecular weight of the dimethylated product molecule (4) was found. Little 
formation of the product in no dithionite control is probably due to the presence of pre-
reduced clusters in the enzyme .  
 
  
 
 
Scheme 7.8: Reaction catalyzed by MJ0619 in presence of SAM and dithionite 
 
 
No incorporation of deuterium was observed when CD3 SAM was used (Figure 
7.21). All other preps only gave the negligible quantity of the product with very low 
counts. The addition of methylene tetrahydrofolate, methyl tetrahydrofolate or 
methylcobalamin did not make any difference in any of the product formation, suggesting 
that they are not involved in the reaction. 
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Figure 7.21: Product formation is observed in the reaction conducted with CD3
 – SAM. 
No deuterium incorporation was observed. 
 
These observations clearly suggest that none of those compounds mentioned above 
are methyl donors. Thus, it is proposed that the enzyme comes with a very loosely bound 
methyl donor which can be lost during the purification process. Not all the enzyme preps 
have an equal amount of the methyl donor bound and hence all of them are not active for 
methylation. 
 
7.3 Discussion 
MJ0619 has been predicted as a radical SAM enzyme, and it has four putative 
cysteine containing motifs that are conserved in many orthologs. These cysteine 
containing motifs are used to harbor at least three 4Fe-4S clusters. Among these four 
motifs two are canonical CX3CX2C motifs, characteristics of radical SAM family of 
proteins. To understand the protein’s activity, the protein was overexpressed and 
anaerobically purified and analyzed by SDS-Page gel and UV-Vis spectroscopy. The data 
confirmed overexpression of pure protein and the presence of 4Fe-4S clusters in it. 
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Estimation of iron and sulfur content of the protein suggested the presence of more than 
two clusters which was confirmed by the presence of the UV band at 418 nm, in M3 mutant 
where both the canonical motifs were mutated. Two different signals were observed in the 
EPR spectra with g values 2.01 and 2.06, of the wild-type enzyme indicating the presence 
of two different types of clusters. In the presence of either of the canonical motifs, both 
the signals are present. However, when both are mutated (M3) the signal at g = 2.01 was 
absent. This observation indicates that the type of the iron-sulfur clusters bound by the 
canonical and non-canonical motifs are different and can be differentiated by EPR 
spectroscopy. 
Another characteristic of radical SAM enzymes is the formation of 5’-
deoxyadenosine (13) when incubated with SAM (11) and sodium dithionite even in the 
absence of the substrate. Wild-type MJ0619 was also incubated under the same condition 
and formation of 13 was observed. The reaction was slow at 37 oC, but quite fast at 70 oC. 
This observation clearly confirms that MJ0619 is a radical SAM enzyme, can cleave SAM 
reductively to generate 5’-deoxyadenosyl radical. 
Allen et al. proposed that both of the two 4Fe-4S clusters are responsible for the 
generation of one 5’-deoxyadenosyl radical each and thus catalyze two consecutive 
methylations of the pterin moiety. There was no report in the literature where two 4Fe-4S 
clusters located so close to each other in one enzyme and can have radical SAM activity 
independently. To test this hypothesis these cluster binding motifs were mutated and it 
was found that only M1 mutant is active but M2 or M3 mutants are not. This observation 
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clearly indicates that only the cluster harbored by the second canonical motif (CL-2) is 
responsible for SAM cleavage. 
As the in vivo analysis was performed in E. coli, the efficiency of 
flavodoxin/flavodoxin reductase reducing system was also tested on MJ0619. Formation 
of 5’-deoxyadenosine indicates that the enzyme would show its native activity inside the 
cell. 
In SEED database, MJ0619 was annotated as a distant ortholog of MoaA, a 
molybdenum cofactor biosynthetic enzyme, that uses GTP (6) as a substrate.141 This 
information led us to the testing of GTP as a substrate for MJ0619. Two new peaks were 
found that has the UV-spectrum similar to 7,8-dhydropterin moiety. Upon treatment with 
calf intestinal phosphatase (CIP), one of them changed position and the other remained 
the same. These peaks were later identified as 7,8-dihydroneopterin-3-triphosphate (15) 
and 7,8-dihydroneopterin-2,3-cyclic phosphodiester (7). A time course experiment with a 
mesophilic ortholog of MJ0619 shown that the linear triphosphate is the first intermediate 
to be formed which was later converted to the final product 7. The aerobically purified 
enzyme that was expressed without added iron and sulfur does not show the 
cyclohydrolase activity which indicates that the presence of the cluster is essential. 
Apart from the pterin products two other major peaks were found in the 
chromatogram which was later identified as guanosine and guanine. The presence of these 
two peaks indicates the phosphatase and nucleoside hydrolase activity of the MJ0619 
enzyme. It was also observed that MJ0619 can accept awide range of nucleosides as 
substrates for the N-glycosidic bond cleavage. Neither SAM nor dithionite was found 
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essential for any of these activities. However, the presence of Mg2+ ions facilitates the 
dephosphorylation of GTP. 
The proposed substrate (3) was reacted with MJ0619. In some of the preps 
formation of the desired dimethyl product (4) was detected by LC-MS. It has the same 
exact mass with the product standard and comes at the same retention time in the 
chromatogram (Figure 17). No incorporation of deuterium from CD3 labeled SAM negates 
the possibility of SAM or methionine to be the source of the methyl group. No product 
formation was detected with any mutant enzyme. As the product formation was observed 
only with few preps we hypothesize that some of the preps co-purify with some unknown 
methylating agent that is not derived from methionine or serine, however, can be 
biosynthesized from acetate. 
In conclusion, MJ0619 is a radical SAM enzyme that has at least three 4Fe-4S 
clusters bound in it and can catalyze the reductive cleavage of SAM to generate 5’-
deoxyadenosine radical. It also has GTP cyclohydrolase and nucleoside hydrolase type 
activity in addition to it. It gives dimethyl pterin product 4 formations when 7,8-dihydro-
6-hydroxymethyl pterin (3) was used as the substrate. Further investigation is required for 
a better understanding of the mechanism of this enzyme. 
 
7.4 Experimental 
7.4.1 Overexpression and purification of MJ0619 
The pTHT vector containing the MJ0619 encoding gene was transformed into 
Escherichia coli Bl-21(DE3) harboring the SUF operon containing plasmid. The starter 
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culture was prepared by  growing the cells aerobically for 12-15 h at 37 °C in 15 mL of 
LB medium supplemented with 40 μg/mL kanamycin and 25 μg/mL chloramphenicol. A 
larger culture of  1.5 L of LB medium, supplemented with 40 μg/mL of kanamycin and 
100 μg/mL of chloramphenicol was then inoculated with the starter culture. After growing 
aerobically (180 rpm) at 37 °C for 3-4 hours until the A600 was 0.5-0.6. The cultures were 
then cooled to 4 °C and ferrous ammonium sulfate (140 mg/L) and L-cysteine (140 mg/L) 
were added. The protein expression was induced by the addition of 200 μM of isopropyl-
1-thio-β-D-galactopyranoside (IPTG, LabScientific). The cultures were grown with slow 
shaking (110 rpm) at 15 °C for an additional ~ 18 h. and the cells were harvested by 
centrifugation at 5000 rpm in a Beckman Coulter Avanti J-26 XPI with a JLA-8.1000 rotor 
(15 min at 4 °C). The cell pellet (~ 3.0 g per liter of larger culture) was stored in liquid 
nitrogen until use. Cell lysis and protein purification were carried out in a glove bag 
(CoyLaboratories) under the anaerobic atmosphere of 5% hydrogen and 95% nitrogen. 
Stored cells were thawed at room temperature  and resuspended in 30 mL of Lysis Buffer 
(100 mM Tris-HCl, pH 7.5 at 25 °C) 20 mg of lysozyme and 5uL of benzonase nuclease 
(Sigma) was added to it. The entire mixture was incubated on ice for 1.5 hours with 
continuous stirring and then the cells were lysed by sonication, for 5 × 120 s using a 
Misonix Sonicator XL-2000 (setting = 9) with 10 minutes interval with stirring.  After 
centrifugation at 15,000 rpm in a Beckman Coulter Avanti J-E with a JA-17 rotor for 30 
min at 4 °C, the cell debris was discarded and the cell lysate was passed through a 0.45 
μm syringe filter. To purify MJ0619 protein by nickel-NTA affinity chromatography 5 
mL HiTrap chelating HP column (GE Healthcare Life Sciences) was charged with 2 
 138 
 
column volumes (CV) of 0.1 M NiSO4, washed with 5 CV of filtered water to remove 
excess nickel, and equilibrated with 3 CV of Lysis buffer. The filtered cell lysate was 
loaded onto the column at 1 mL / min flow rate and the resin was washed with 10 CV of 
Wash Buffer (100 mM Tris-HCl, 300 mM NaCl, 30 mM imidazole, pH 7.5 at 25 °C) 
Finally the protein was eluted with an elution buffer (100 mM Tris-HCl, 300 mM NaCl, 
250 mM imidazole, pH 7.5 at 25 °C). The fractions with dark greenish black color contain 
the desired protein which is pooled and the buffer was exchanged to the storage buffer(100 
mM potassium phosphate, pH 7.5 at 25 °C, 2 mM DTT, 30% glycerol) via Econo-Pac 
10DG size exclusion chromatography (Bio-Rad) and stored in liquid nitrogen. The protein 
concentrations were measured by Bradford assay and the SDS page gel analysis showed 
the His-tagged protein molecular weight ~ 60 kDa. 
 
7.4.2 Estimation of the iron content 
Iron content was analyzed via a protocol described in the literature.142 Following 
reagent solutions were prepared for this purpose:  
Solution A: 8 M guanidine hydrochloride, Solution B: 10 mM aqueous ferrozine 
(3-(2-Pyridyl)-5,6-diphenyl-1,2,4-triazine-p,p’-disulfonic acid monosodium salt hydrate), 
Solution C: 100 mM L-ascorbic acid in water, Solution D: saturated ammonium acetate 
solution, Solution E: 2M HCl. To 100 μL of enzyme solution containing 0 to 50 μM 
MJ0619, 100 μL of solution A and Solution E were added and the solution was diluted to 
550 μL. The resulting solution was centrifuged to remove any denatured protein. To 500 
μL of the supernatant, 30 μL of the solution C and 30 μL of  solution D were added, mixed 
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thoroughly and incubated at RT for 30 min. The absorbance of the iron ferrozine complex 
was recorded at 562 nm using a Varian Cary Bio 300 UV-Visible Spectrophotometer 
(extinction coefficient for iron ferrozine complex is 27.9 mM-1cm-1). A standard curve 
was also prepared with known iron concentration under identical conditions using 
Fe(NH4)2(SO4)2 with a concentration range from 0 to 100 μM. The iron content of the 
protein sample was measured using this standard calibration curve. 
 
7.4.3 Estimation of the sulfur content 
Sulfide content was analyzed using the methylene blue assay.142 Following reagent 
solutions were prepared for this assay:  
Solution A: 1% (w/v) zinc acetate, Solution B: 3 M NaOH, d Solution C: 0.1 % 
N,N-dimethyl-p-phenylenediamine (DMPD) monohydrochloride in 5 M HCl and Solution 
D: 23 mM FeCl3 in 1.2 M HCl. To a 300 μL solution of the protein ( 0 – 10 uL) 1 ml of 
solution A was added followed by 50 μL of  solution B: 50 μL of. This mixture was gently 
vortexed and 250 μL of solution C and 50 μL of Solution D were added. The resulting 
solution was vortexed in an interval 5 min over a 30 min. After centrifugation of the 
sample solutions at 15,000 rpm in an Eppendorf 5424 R with an F45-24-11 rotor for 5 min 
at 25 °C the supernatant was collected and the absorbance at 670 nm was recorded using 
a Varian Cary Bio 300 UV-Visible Spectrophotometer. A standard curve that was also 
generated under identical conditions using a fresh solution of sodium sulfide (Na2S; 
Sigma-Aldrich) in 0.1 M NaOH with a concentration range from 0 to 150 μM. The sulfide 
 140 
 
content of the protein was determined by comparing the unknown readings with the 
standard curve.  
 
7.4.4 Assay for radical SAM activity 
Following are the concentration of different components used to determine the 
radical SAM activity of the MJ0619 protein. Buffer – 100 mM tris, pH-7.5, SAM – 1.3 
mM, Dithionite – 3 mM Enzyme ~ 60 μM. For the high-temperature reaction, the 
components were mixed together and the mixture was heated at 70 oC for 20 minutes. For 
the low temperature, the same reaction mixture was incubated at 37 oC for 24 hours. After 
the incubation, the reaction mixture was cooled on ice, centrifuged and the supernatant 
was passed through a 10 kDa cutoff filter and the filtrate was analyzed by HPLC or LCMS. 
 
7.4.5 Radical SAM activity with FldA / FldR system 
Assay was carried out by mixing the following components: Buffer – 100 mM tris, 
pH-7.5, SAM – 1.3 mM, Dithionite – 3 mM Enzyme ~ 60 μM, FldA – 30 μM, FldR – 30 
μM NADPH – 1.5 mM were mixed together by pipetting. The mixture was incubated at 
37 oC for 24 hours. After heat denaturation and filtration the reaction mixtures were 
analyzed by LCMS.  
 
7.4.6 Assay for GTP cyclohydrolase activity 
Following components were mixed to the designated final concentration: Buffer – 
50 mM tris, pH-7.5, GTP – 2 mM, MnCl2 2mM, Enzyme (MJ0619) ~ 90 μM. After mixing 
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all these components together the reaction mixture was heated at 70 oC for 20 minutes. 
After incubation, the reaction mixture was cooled on ice, centrifuged and the supernatant 
was passed through a 10 kDa cutoff filter and the filtrate was analyzed by HPLC and 
LCMS. 
 
7.4.7 Assay with 7,8-dihydro-6-hydroxymethyl pterin 
Following are the concentration of different components used to for the reaction 
of MJ0619 protein with 7,8-dihydro-6-hydroxymethyl pterin. Buffer – 100 mM tris, pH-
7.5, SAM – 1.3 mM, Dithionite – 3 mM, Substrate – 1 mM and  Enzyme ~ 60 μM. The 
reaction mixture was incubated at 37 oC for 24 hours. After the incubation, the enzyme 
was heat denatured at 70 oC for 20 min, cooled on ice, centrifuged and the supernatant was 
passed through a 10 kDa cutoff filter and the filtrate was analyzed by HPLC or LCMS. 
 
7.4.8 HPLC method 
HPLC analysis using a linear gradient, at a flow rate of 1 mL/min was used with 
absorbance detection at 254 nm. Solvent A is water, solvent B is 100 mM K2HPO4, pH 
6.6 and solvent C is methanol: 0 min, 100% B; 7 min, 10% A, 90 % B; 12 min, 20 % A, 
65 % B, 15 % C; 22 min, 25 % A, 10 % B, 65 % C; 25 min, 25 % A, 75% B; 32 min, 100 
% B; The analysis was done in an Agilent 1260 series instrument using a Agilent Eclipse 
XDB HPLC column (15 cm x 4.6 mm, 5 μM particle size). 
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7.4.9 LCMS method 
Samples were analyzed by reverse-phase HPLC on an Agilent 1200 HPLC system 
equipped with a thermostatted autosampler (10 °C). The stationary phase was Supelcosil 
LC-18-T (15 cm × 3 mm, 3 μm particles), maintained at 22 °C. The LC eluent consisted 
of a gradient of 75% methanol in 25% water with 5 mM ammonium acetate buffer, pH 6.6 
(0.4 mL/min flow rate). The percentages of ammonium acetate buffer (B) and methanol 
(M) at time t varied according to the following scheme: (time Methanol, Buffer): (0,0,100), 
(7,0,100), (10,20,80), (27,100,0), (18,100,0), (29,100,0); (30,0,100); (40,0,100). 
Compounds were detected using absorbance at 254 nm and also by extracted mass 
chromatogram. Mass data were collected using an in-line Bruker Daltonics micrOTOF-Q 
II ESI-Qq-TOF mass spectrometer (HyStar) in positive ion mode as indicated. 
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